( 12 ) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY ( PCT ) . ( 19 ) W0rld Intellectual Pr0perty Organizati0n. Internati0na1 Bureau. . ( 43 ) Internati0nal Publicati0n Date 22 April 2010 ( 22.04.2010 ) . . ‘. r . , i a . - : . - _ l. a . ( 10 ) Internati0nal Publicati0n Number. WO 2010 / 043029 A1. . ( 51 ) . ( 21 ) . ( 22 ) . Internati0nal Patent Classiﬁcati0n : A6 ] K 3 ] / 7004 ( 2006.01 ) A6 ] P 35 / 00 ( 2006.01 ) A61K 45 / 00 ( 2006.01 ) . Internati0nal Applicati0n Number : PCT / CA2009 / 001440. Internati0nal Filing Date : 8 Oct0ber 2009 ( 08.10.2009 ) . ( 81 ) . Designated States ( anZeSS 0therwise indicated , f0r eveiy kind 0f nati0na1 pmieciiOn availabZe ) : AE , AG , AL , AM , AO , AT , AU , AZ , BA , BB , BG , BH , BR , BW , BY , BZ , CA , CH , CL , CN , CO , CR , CU , CZ , DE , DK , DM , DO , DZ , EC , EE , EG , ES , FI , GB , GD , GE , GH , GM , GT , HN , HR , HU , ID , IL , IN , IS , JP , KE , KG , KM , KN , KP , KR , KZ , LA , LC , LK , LR , LS , LT , LU , LY , MA , MD , ME , MG , MK , MN , MW , MX , MY , MZ , NA , NG , NI , NO , NZ , OM , PE , PG , PH , PL , PT , RO , RS , RU , SC , SD , . ( 25 ) mm LangWgei EﬂghSh SE , SG , SK , SL , SM , sT , SV , SY , TJ , TM , TN , TR , TT , ( 26 ) Publicati0n Language : Eng1ish TZ , UA= UG= US= UZ= VC= W= ZA= ZM= ZW - . ( 30 ) Pri0rity Data : ( 84 ) Designated States ( anZeSS 0rherwise indicated , f0r eveiy. 61 / 105 , 665 15 Oct0ber 2008 ( 15.10.2008 ) US kind 0fregi0naZ pmteciion avaiZabZe ) : ARIPO ( BW , GH , . GM , KE , LS , MW , MZ , NA , SD , SL , SZ , TZ , UG , ZM , . ( 72 ) Invent0rs ; and ZW ) , Eurasian ( AM , AZ , BY , KG , KZ , MD , RU , TJ , . ( 71 ) Applicants : WANG , Xingn0ng [ CA / CA ] ; 1071 Ruthi - TM ) , Eur0pean ( AT , BE , BG , CH , CY , CZ , DE , DK , EE , . ( 74 ) . 11a AVenue , N0rth Vanc0uVer , British C01umbia V7R 2E7 ( CA ) . WEI , Y0ucheng [ CAfCA ] ; 1071 Ruthina AVenue , N0rth Vanc0uVer , British C01umbia V7R 2E7 ( CA ) . Agent : TAYLOR , Euan , R. ; DaVis LLP , 2800 Park. Es , FI , FR , GB , GR , HR , HU , IE , IS , 1T , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , R0 , SE , SI , SK , SM , TR ) , OAPI ( BF , BJ , CF , CG , CI , CM , GA , GN , GQ , GW , ML , MR , NE , SN , TD , TG ) . P1ace , 666 Burrard Street , Vanc0uVer , British C01umbia Published : . V6C zz7 ( CA ) . with internari0naI Seareh rep0rt ( Ari. 21 ( 3 ) ) . . ( 54 ) Title : USE OF TETROSE TO INHIBIT CANCER AND TO INCREASE CELL VIABILITY. W0 2010 / 043029 A1 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. ( 57 ) Abstract : There are disc10sed meth0ds f0r inhibiting the gr0Wth 0f cancer ce11s 00mprising direct1y 0r i11direct1y eXp0sing the cancer ce11s t0 a pharmaceutica11y effectiVe 00ncentrati0n 0f tetr0se. There are a1s0 disc10sed meth0ds f0r treating a mit0ch0ndriaI dis0rder II1 a subject haVing such dis0rder , the meth0d 00mprising direct1y 0r indirect1y administering t0 the subject an effectiVe d0se 0f tetr0se. There are a1s0 disc10sed 00mp0siti0ns f0r use in the meth0ds. 10. 15. 20. WO 2010 / 043029 PCT / CA2009 / 001440. USE 0F TETROSE TO lNH|B|T CANCER AND TO |NCREASE CELL V|ABlL|TY FlELD. The subject appIication relates to therapeutic uses ot tetroses and compositions comprising tetroses. BACKGHOUND. US Patent No. 7465734 Shephard , issued December 16 , 2008 discloses the use of oxetanes as a constituent group ot a prodrug. US Patent No. 6642205 Klyosov , issued November 4 , 2003 disc|oses the use oi tetroses as spacers in therapeutic compounds. PCT Patent Application WO04050100 Berrada , fi|ed December 3 , 2003 , discloses. the use of combination ot a chitosan and a sa|t oi erythru|ose or threose to treat a tumor. US Patent Application No. 9 / 830 , 912 Jariwa||a , Fi|ed Apr 30 , 2001 disc|oses the use oi threonate either a|one or in combination with ascorbate , to promote apoptosis. PCT Patent Application WO07074344 Knox , Fi|ed December 29 , 2006 , discloses. the use of erythrose , erythru|ose , and 3 - hydroxy - 2 - butanone to assist processing ot a prodrug. SUMMARY OF THE |NVENT|ON. |n a iirst embodiment , there is disc|osed a method for inhibiting the growth oi a cancer cell. The method may comprise directly or indirectly exposing the cancer cell to a pharmaceuticaHy etfective concentration ot tetrose. ln alternative embodiments , the tetrose may have a structura| tormula selected from the group consisting of : . WO 2010 / 043029. . . . . PCT / CA2009 / 001440 C4H3O4 H o H \ i \ c CH2OH H— ' C—OH lc=o HO—C—H H—|C - —OH H—|C—OH H - C—OH |CH2OH |cH2oH cH2oH C4H5O4 o i H o H o H c \ ﬂ \ r \ I ( I ( |3 ( i H—C—OH c=o o=c H—C—OHHO—C—H H~c—oH H—C—OH H— - ( |3—OH d=o é l I | \ CH2OH CH2OH CH2OH cH2oH H o H o \C / H O H H o I \ / \ \ / HO - C—H ? ? H - Cl3—OH ( ﬁ - 0H H0 - C H—C - OH HO—C|3—H 33 C—OH c—oH C - OH C——OH / / \ I II o H CH2OH CH2OH cHoH C4H303 H o H o H o \ n \ / \ \ i c c c c H - —O— - H H—é—H H - C|3 - 0H HO - C - - H H - Cl3 - OH H— ( %—OH H— ( i—oH H—<i—H H—C - H H— ( |3—OH cH2oH ciH2oH CH2OH CH2OH C|H3 H o \ / c Ho - < ' : - H H - é - oH C|H3. . . WO 2010 / 043029. . . . PCT / CA2009 / 001440 CaH5O3 H\ JO \ ¢O H\ / O H\ / O C C i i C=o 0= ( | : H—C—H H— ( |3—H MM . - 2. A0 i=° CH20H ( |3H2OH CH2OH CH2OH H O O H o H 0 \ / \ i \ / \ / C C C C aaa H - é - H mm Ho - c ' ; - H H - C—0H H - ( I3 - OH H—C|3 - H H—C—H A i A J : / \ / \ / \ / \ H 0 H H 0 o H H 0 O H 0 H 0 \ / \ / \ / / \ / C C C C I I I I C—OH H0—C C - - H H - C || II II II C—H C—H C—OH C - OH CH2OH CIH2OH CH2OH ciH20H C4H4O4 H O H O H O \ / \ / \ i H 0 0 C C C \ i \ i I I I 0 ff ( I=O o = ( | : H—C|3 - —OH <f=O 0=C|3 H - C - OH H—C—oH c=o C=O C=O é é ( l : | I / \ / \\ / \\ CH2OH CH2OH H o H 0 H O H o \ / / C Ho..é - H C / \ H O. . . . . W0 2010 / 043029 PCT / CA2009 / 001440 CaH4O3 H O H O H O \ / \ / \ / H O H O C C C \ I \ i I | I C CI C=O =C| H—C - H C|=0 0=Ci H—C - H H—C—H C=o C=0 C=O C C CI l | / \ / ' \\ / \ CH3 CH3 H O H O H O H O \ i C I H—C— é=o é / ‘\\.~ H O C4H502 H O H O \C / H\ ¢0 H\ 4 ' 0 \ / H\ / O | i i i C “"i“ C=O O=C H—C—H H - C|—H H—C—H H— ( |3—H - ( l3 - H ( i=0 C|=O O I | I I / \ CH3 CH3 CH3 CH3 H O H O \ / C H - O—H H—C|— - H é / \ O H. . . . 10. 15. WO 2010 / 043029. . . . PCT / CA2009 / 001440 CaHaO2 H o H o H o H o H o H 0 \ y \ I \ i \ n \ f \ y. i i i i i i H—C - OH HO—C—H H—C—H H—C - H H—C—H H—C - H H—C - H H—é - H H—C—OH H—c—oH H—C—H H - %—H. ( |3H3 ( |3H3 ( |3H3 CH3 ( |3H2OH CH2oH. . and any pharmaceutica|ly eiiective derivatives thereoi. In aIternative embodiments , the derivative may be a conjugated , substituted , . ionised , saIt , isomeric , acid , base , aIdehyde , ketone , alcohol , amine , amide , thio| , ring or |inear iorm. In aIternative embodiments the tetrose may be selected irom the group consisting oi erythrose , threose and erythru|ose. In a|ternative embodiments , the indirect exposing may comprise exposing the cancer ceII to a prodrug metabo|isable to release tetrose. In alternative embodiments the cancer ce|I may be exposed to a concentration oi greater than about 100 mg / litre of tetrose and exposed to a qucose concentration. oi greater than about 500 mg / Iitre beiore or simuItaneous with the exposure to tetrose. In aIternative embodiments , the cancer may be selected irom the group consisting oi carcinoma , sarcoma , adenoma , leukemia , |ymphomas and myeloma. |n alternative embodiments , the exposure may occur in combination with exposing the ceII to a modu|ator oi carbonic anhydrase activity. ln alternative embodiments , the modulator may comprise a Zinc sa|t. 10. 15. 20. 25. WO 2010 / 043029 PCT / CA2009 / 001440. |n aIternative embodiments , there is disc|osed a method ior improving the viabiIity 0i a ce|l , the method may comprise direct|y or indirectIy exposing the ceI| to a therapeuticalIy eiiective amount oi tetrose. In a|ternative embodiments , the derivative may be a conjugated , substituted , ionised , saIt , isomeric , acid , base , a|dehyde , ketone , aIcohoI , amine , amide , thioI , ring or linear iorm. ' . In aIternative embodiments , the exposure may occur in combination with exposing the cell to a modulator oi carbonic anhydrase activity. The ce|I may be under conditions oi |imited energy supply and may have a mitochondriaI disorder. |n a|ternative embodiments , the tetrose may be se|ected irom the group consisting of erythrose , threose and erythrquse. In aIternative embodiments , indirect exposing may comprise exposing the ce|I to a prodrug metabolisab|e to release tetrose. ln a|ternative embodiments , the methods oi embodiments may comprise exposing the ceIIs to a concentration oi between about 1 mg / |itre and about 200 mg / Iitre of the tetrose to increase the viabiIity oi cell. In alternative embodiments , the mitochondria| dis0rder may be associated with a disorder seIected irom the group consisting oi neurodegenerative disease , AIzheimers disease , Parkinsons disease , Huntingtons disease , cardiovascu|ar disease , stroke , obesity , diabetes , muItipIe sc|erosis , systemic Iupus erythematosis , rheumatoid arthritis , schizophrenia , bipo|ar disorder , depression , ataxia , autism , epilepsy , migraine , Batten disease , Lactic acidemia , Lebers. disease , mitochondriaI cardiomyopathy and myopathy , parap|egin , NASH , and WiIsons disease. In a|ternative embodiments , there is discIosed a method oi treating a mitochondria| disorder in a subject having such disorder , the method may. 10. 15. 20. 25. WO 2010 / 043029 PCT / CA2009 / 001440. comprise direct|y or indirect|y administering to the subject a pharmaceuticaIIy etiective dose oi tetrose. In a further embodiment there is discIosed a composition which may comprise a direct or indirect source oi tetrose in an amount etiective to inhibit the growth oi a cancer ce|I ; and a pharmaceuticaIIy acceptabIe carrier or diIuent. ln a iurther embodiment there is discIosed a composition which may comprise a direct or indirect source oi tetrose in an amount eiiective to increase the viabiIity oi. a ce|| having a mitochondria| disorder ; and a pharmaceuticaHy acceptabIe carrier or diluent. |n a iurther embodiment there is disc|osed the use oi an eiiective dose oi a direct or indirect source oi tetrose to achieve an etfect se|ected irom the group consisting oi : inhibiting the growth oi a cancer ceI| ; increasing the viabi|ity of a ceII under low energy conditions ; and increasing the viabi|ity oi a cell having a mitochondrial disorder. In a iurther embodiment there is discIosed the use ot a prodrug to manuiacture a dietary suppIement. |n a iurther embodiment there is discIosed a composition which may comprise a. prodrug metaboIisabIe to yieId a pharmaceuticaIly eiiective amount oi tetrose. In a turther embodiment there is discIosed the use oi tetrose to manuiacture a medicament ior : inhibiting the growth oi a cancer cel| ; or improving the viabi|ity oi a ce|I exhibiting a mitochondria| disorder. Other objects , ieatures and advantages oi the present invention wiI| become apparent from the foIlowing detai|ed description. lt shou|d be understood , however , that the detaiIed description and the speciiic examples whiIe indicating preierred embodiments of the invention are given by way oi iIlustration onIy , since various changes and modiiications within the spirit and scope oi the invention wiIbecome apparent to those skilled in the art irom this detaiIed description. 7. 10. 15. 20. 25. WO 2010 / 043029 PCT / CA2009 / 001440. DETAlLED DESCRIPT|ON 0F THE INVENT|ON. Deiinitions. In this disclosure the term “in combination with" means that the eIements or procedures to be combined may be mixed , or may be used simuItaneous|y , or sequentiaIIy , or in any other way temporal|y , spatiaI|y or otherwise combined. In this discl0sure an “eiiective amount” oi a compound means a therapeutica|Iy eifective amount , a prophyIacticaIly eifective amount , or a nutritionaIIy effective amount as the case may be or as the context requires. In embodiments a therapeutic , nutritiona| or prophyIactic result may comprise stopping or s|owing or preventing the progress oi a disease ; and may include inhibiting growth oi or division oi cancer ceIls , or increasing tumor apoptosis , or causing the shrinking , or disappearance oi a tumour. Those ski|Ied in the art wiII recognise that what constitutes an “etiective amount” oi a compound may very according to a variety oi iactors inc|uding but not Iimited to the nature and extent of progression oi a disease state , and the age , sex , and weight oi the subject. In embodiments “eiiective amounts” may be comprised in one or more dosages oi the same or diiierent types or quantities , spread over a desired time period , and may be adjusted as necessary in ways readin apparent to one ski|Ied in the art. |t wi|l be understood that those skiI|ed in the art wiII avoid dosages and combinations that wou|d cause unacceptabIe deIeterious etiects on the subject. |n this discIosure a “ceI|” or “tissue” may be iso|ated , may be comprised in group oi ceIIs , may be in cuIture , or may be comprised in a Iiving subject and may be a mamma|ian cel| and may be a human celI. In this disclosure “cancer” ”means and incIudes any ma|ignancy , or ma|ignant celI division or malignant tumour , or any condition comprising uncontro|Ied or inappropriate cel| proIiieration and incIudes without Iimitation any disease characterized by uncontrolIed or inappropriate ce|I pro|iferation. ln embodiments cancers celIs may exhibit mitochondria| disorders , deiiciencies or dysiunctions. ln embodiments cancer may incIude but is not Iimited to carcinomas , sarcomas , . 8. 10. 15. 2O. 25. 30. WO 2010 / 043029 PCT / CA2009 / 001440. adenoma , |eukemias , |ymphomas and myeIomas. ln particu|ar embodiments a cancer may include carcinoma , adenocarcinoma , adenoma , sarcoma , Iymphoma , and Ieukemia. ln particuIar embodiments a cancer may be or may incIude B|adder Cancer , Breast Cancer , Co|on and Fiecta| Cancer , Endometrial Cancer , Kidney ( Rena| CeIl ) Cancer , Leukemia , Lung Cancer , Me|anoma , Skin Cancer ( Nonme|anoma ) , Non - Hodgkin Lymphoma , Pancreatic Cancer , Prostate Cancer , Thyroid Cancer , Stomach Cancer , Liver Cancer , Ovarian Cancer. In particu|ar embodiments cancer may be Adrenal Cancer , Anal cancer , ApIastic Anemia , Bi|e Duct Cancer , Bladder Cancer , Bone Cancer , Brain Cancer , Breast Cancer , Bronchus and Lung Cancer , CentraI Nervous System Cancer , CervicaI Cancer , Colon and Fiectum Cancer , Connective Tissue Cancer , CraniaI Nerves Cancer , Digestive organs Cancer , Endometria| Cancer , Endocrine Cancer , Esophageal Cancer , Ewing ' s Fami|y oi Tumors , Ga|Ib|adder Cancer , GastrointestinaI Carcinoid Tumors , Gastrointestinal StromaI Tumors , Gestational Trophob|astic Disease , Head and Neck Cancer , Hodgkin Lymphoma Cancer , Kaposi ' s Sarcoma , Kidney Cancer , LaryngeaI and HypopharyngeaI Cancer , Larynx Cancer , Leukaemia Cancer , Leukaemia - Lymphoid Cancer , Leukaemia - MyeIoid Cancer , Leukaemia of Unspecified CeI| Type Cancer , Lip Cancer , Liver Cancer , Lung Carcinoid Tumors , Lymphoid , Haematopoietic and FieIated Tissues Cancer , Lymphoma Cancer , Malignant lmmunoproliierative Cancer , Ma|ignant Neop|asm Cancer , MaIignant Neop|asm of Genital Organs Cancer , MaIignant Neoplasm oi Urinary Tract Cancer , Meninges Cancer , MesotheIioma Cancer , Mu|tipIe mye|oma Cancer , Mye|odysp|astic Syndrome , Nasa| Cavity and Middle Ear Cancer , Nasopharyngea| Cancer , Nasopharynx Cancer , NeurobIastoma , Non - Hodgkin‘s Lymphoma Cancer , Non - Hodgkin‘s lymphoma , Other and Unspeciiied Cancer , Neurob|asma , Ora| Cavity and Oropharyngea| Cancer , Osteosarcoma , Oropharynx Cancer , Ovarian Cancer , Pancreas Cancer , Parathyroid Cancer , Penis Cancer , Periphera| and Cutaneous T—cell Lymphomas Cancer , PeripheraNerves Cancer , Peritoneum Cancer , Pharyngeal Cancer , Pituitary Tumor , Postcricoid Region Cancer , Prostate cancer , Retinoblastoma , Rhabdomyosarcoma , Sa|ivary GIands Cancer , Sarcoma , Soit Tissue Cancer , MeIanoma Skin Cancer , NonmeIanoma Skin Cancer , Sinus Cancer , SmalI. 9. 10. 15. 20. 25. WO 2010 / 043029 PCT / CA2009 / 001440. Intestine Cancer , Sma|I |ntestine Cancer , Stomach Cancer , TesticuIar Cancer , Thymoma and Thymic Carcinoma , Thyroid Cancer , Tongue Cancer , TonsiI Cancer , Trachea Cancer , Cancer NOS , Urinary Organs Cancer , Urethra| cancer , Uterine Cancer , Uterine Sacrcoma , VaginaI Cancer , Vulvar Cancer , Cancer of Unknown Primary , Waldenstrtim macrogIobuIinemia , and Wi|ms Tumour. In particu|ar embodiment the cancer may be Bladder , Brain , Breast , cervical , Co|orectaI , uterine , Esophagus , Hodgkin Iymphoma , Kidney , Larynx , Leukaemia , Lip , Lung , MuItiple myeIoma , Non - Hodgkin lymphoma , OraI cavity , Ovary , Pancreas , Prostate , Skin , Stomach , Testicular , or Thyroid cancer. In particuIar embodiment the cancer may be Stomach Cancer , Lung and Bronchus Cancer , Liver Cancer , Esophageal Cancer , Breast Cancer , Co|on and FtectaI Cancer , Prostate Cancer , CervicaI Cancer , Uterine Cancer , Ora| Cancer , Sarcoma , B|adder Cancer , Melanoma , Ovarian Cancer , EndometriaI Cancer , Pancreas Cancer , Kidney ( FienaI CeII ) Cancer , Lymphoma , or Leukemia. |n particuIar embodiments the cancer may be ductal carcinoma , gliobIastoma , epitheIioid carcinoma , adenocarcinoma , carcinoma , or erythro|eukemia , . |n this discIosure the term “nutritional suppIement” means a preparation intended to provide suppIementary nutrients that are not present in suiiicient quantity or desired quantity in a subjects diet. In this disc|osure the terms “direct|y exposing” , “directly administering” and the like , a ceII or tissue to tetrose , means that the cell or tissue is exposed to a composition or medium , which may without limitation be a iIuid , comprising free tetrose. In this discIosure the terms “indirectly exposing” , “indirectIy administering” or the |ike of a ceIl or tissue to tetrose means that the cel| or tissue is exposed to a. prodrug or other composition that is metabo|isab|e to reIease a pharmaceutical|y effective amount oi iree tetrose. In this disc|osure the term “modulator” means a chemical whose presence modifies the behaviour oi an enzyme , which may be a carbonic anhydrase. 10. 10. 15. 20. 25. 30. WO 2010 / 043029 PCT / CA2009 / 001440. enzyme. In embodiments a moduIator may be or may comprise Zinc , or a zinc saIt , or a carbonic anhydrase inhibitor. ' . In this disclosure the term “prodrug” means an inactive iorm oi tetrose , that is or may be converted into an active iorm oi tetrose by normal metabolic processes. Without Iimitations , an active iorm oi tetrose may be or may comprise a iree tetrose monosaccharide. It wiII be understood that an “inactive form” of. tetrose means a iorm oi tetrose that is not directIy metaboIicaIly avai|abIe to a ceII and in embodiments inactive tetrose may be or may incIude tetrose that is conjugated , modiiied , derivatised , compIexed , isomerised or in any other iorm , which can be converted to an active iorm oi tetrose by a ce|I. In particu|ar embodiments a prodrug may be or may comprise any metaboIisable disaccharide or ponsaccharide iorm oi tetrose that is metabo|ised to reIease active tetrose. A wide range oi a|ternative prodrug iorms oi tetrose wiII be readi|y recognised , selected among , synthesised and used by those skiIIed in the art. In particular embodiments a prodrug may be or may comprise heptose , sedoheptu|ose , mannoheptulose , ascorbate , or Vitamin C and in embodiments may be used to treat non - cancerous conditions. |n embodiments the prodrug may be or may comprise heptose , may comprise a monosaccharide having the moIecu|ar iormu|a C7H1407 and may be or may comprise sedoheptu|ose , mannoheptulose. ln particu|ar embodiments any one or more compounds in the ioregoing deiinition may be echuded. |n particular embodiments , which may be embodiments ior the treatment oi cancer , such echuded compounds may be or may comprise mannoheptulose , Vitamin C and ascorbate. In this disc|osure a “limiting supp|y” or “Iimited avaiIabi|ity” and simi|ar terms , oi a sugar or other chemicaI or substrate or of energy supp|y , means circumstances wherein the suppIy oi a suitabIe metabo|isab|e chemical has the efiect oi |imiting the growth or viability of the cel| or the normal chemica| and physicaI processes oi the ce|I or wherein the ce|l is unabIe to utiIise avaiIabIe substrates effectively to maintain a suitable energy suppIy. Simi|ar|y “qucose deiiciency” means that a ce|I has a |ow internal g|ucose concentration that may arise irom causes incIuding |ow. qucose supply or deiicient abiIity to absorb glucose or metaboIise other chemica|s. 11. 10. 15. 20. 25. 30. WO 2010 / 043029 PCT / CA2009 / 001440. t0 |iberate intrace||u|ar g|ucose. SimiIarIy “energy deiiciency“ and simi|ar terms mean that the ceIl is unabIe to maintain a suitab|e energy supp|y because oi g|ucose deiiciency or because oi an inability to properIy or eiiicient|y use g|ucose 0r ketone bodies , or pyruvate or their metaboIites to generate energy , as the case may be. ln this disc|osure the term “mitochondrial disorder” means any condition or disorder which is partly or whoIly , directIy or indirectIy caused by mitochondriaI deiiciency or dysiunction and in aIternative embodiments may incIude but is not |imited to cancer , aging and neurodegenerative disease. In embodiments mitochondrial disorders may be characterised by inability oi ceIls to properly or efiicient|y use glucose or ketone bodies , or pyruvate or their metabolites to generate energy. Without Iimitation such diseases may incIude but are not Iimited to AIzheimers disease , Parkinsons disease , Huntingtons disease , cardiovascu|ar disease , stroke , obesity , diabetes , muItipIe sc|erosis , systemic |upus erythematosis , rheumatoid arthritis , schizophrenia , bipo|ar disorder , depression , ataxia , autism , epiIepsy , migraine , Batten disease , Lactic academia , Lebers disease , mitochondriaI cardiomyopathy and myopathy , parapIegin , Nona|cohoIic steatohepatitis ( NASH ) , and WiIsons disease. In this disclosure the term “inhibit” where used with reierence to cancer ceI|s or the growth or development thereoi , means and inc|udes any eiiects that resuIt in 0r comprise slowing or preventing growth or ceI| division oi the ce|Is , ki||ing the. celIs , disabling the celIs , and in any way reducing the viabiIity , rate oi division or longevity of the ceI|s. |n this disclosure the term “tetrose” means without |imitation , pharmaceuticaIIy eifective monoshaccharides with the molecuIar iormuIa CaHaO4 or that are otherwise represented by any oi the structura| iormu|ae set out in TabIe A and without |imitation may incIude any pharmaceuticaHy eifective derivatives oi any oi the ioregoing including without |imitation any conjugated iorms , substituted iorms , ionised iorms , salts and isomers inc|uding D and L stereoisomers , and any acid , base , aIdehyde , ketone , a|cohol , amine , amide , thioI , ring and |inear iorms oi any. 12. 1O. WO 2010 / 043029. PC T / CA2009 / 001440. oi the ioregoing. In particuIar embodiments “tetrose” may be or may incIude. erythrulose , erythrose , threose , deoxy - tetrose , dehydro - tetrose , and deoxy - . dehydro - tetrose and any D and L isomers thereoi. In embodiments , tetrose may. be or comprise erythrose , erythru|ose or threose , and in seIected embodiments. may be or may comprise D—erythrose , L - erythrose , D - threose , L - threose , D - . erythrulose or L - erythrulose. ln particuIar embodiments tetroses may be pure or. may be substantiaIIy pure or may comprise mixtures oi one or more tetroses. Tetroses , derivatives thereoi , and prodrugs comprising the ioregoing , can be prepared by conventionaI methods welI known to those skiI|ed in the art , who wiII readily identiiy , select and utiIise suitabIe tetroses ior particu|ar purp0ses. Tab|e A : IIIustrative non - limiting examples oi tetroses : . . . . C4H3O4 H o H o \ n \ i c FH2OH c H—c_oH c=o HO - C~H H—c—oH H—C—oH H—C—oH CH2OH CH2oH CH2oH C4H504 H o H o H o H o H o \c / \ I \ / \ / ‘\ / I P f 2 ? H—C—OH a=o o=c H—a—oHHo—c - H H_é_0H H~C—OH H—C - OH c=o d=o é | | I | / xx CH2OH CH2OH CH2OH cH2oH ii 0 H o \C / H o H o H o H o | \ / / \ / \ / \ / / HO—C—H ? ? ﬁ ? H~C—OH a—oHrw—ﬁ H—a—oHim—c—H é C—OH C - OH C - OH C—OH a \ I I II II o H CH2OH CH2OH CHOH CHOH. . . 13. . . . . WO 2010 / 043029 PCT / CA2009 / 001440 C , H3O3 H o H o H o H o H o \ n \ I \ n \ / \ y i i i i i H—C| : —H H—C—H H—C—0H HO - C - H H—C—OH H—C| ) - OH H - C| - oH H—Cl2—H H—ci—H H— ( |3—OH CH2OH c|H20H OH2OH c|H2oH OH3 H o \ / / c OH3 C4H5o3 K a‘ ) H\ ¢O H\ / O H\ / O c c c c i=o o=i H - i - H H - i - H H - i - H mm i=o i=o OH2OH CH2OH c| : H2oH cH2oH H 0 H O H o H o \ / \ / \ / \ / r i r i H - a——H H— ( |3—H H—C—OH HO—C - H H—a—oH H— ( |3——OH H— ( I ) —H H—C|3—H c c i i / \ / \ / \ / \ H o o H H o o H H\ / O H\ / / 0 H\ / 0 H\ / O C C c c O—OH HO—C|. ( i - —H H—Ci ( $—H rim c| : |—oH ( |3| - OH CH20H ClH2OH OH2OH c|H20H. . 14. . . wo 2010 / 043029 PCT / CA2009 / 001440 C4H404 H o H 0 H 0 \ / / \ / \ I H 0 H o C C C \ i \ i | | I CI <|3 cf=0 o = ( I H—C—OH C|3=0 0=<|3 H—C—OH H - C - OH C=O C=o C=0 3 A é I l / \ / \ / \ CH2OH CH2OH H o H o H 0 H o \ / C HO— ( l3—H C=o i / ss H 0 C4H4O3 H o H o H 0 \ / / \ / \ / / ' H o H o C C C \ . / / \ / I I I 0 CI a=o o =a H—a - H C|>=0 0=C| H - C—H H - C - H C=0 c=o C=O C d O I I / \ / \ / \ CH3 CH3 H o H o H o H o \ y C MM C / R H o. . . . 15. 10. . . . . W0 2010 / 043029 PCT / CA2009 / 001440 C4H502 H O O \C / H\ / / ' O H\ 4?O H\ / H\ / O I i i i c C=0 0=C H - C—H H— ( _l , —H H—C—H H—C - H H— - ( |3—H CI : =O O=O C I I I I / \ CH3 CH3 CH3 CH3 H 0 H O \ / C I H - C - - H H—Ci - H c ' / \ O H C4Hs02 H O H O H O H O H O H 0 \ / \ / \ / \ i \ 4" \ / C C C C C C H - C - OH HO—C - —H H—C—H H - C - H H—C - H H - ( | : —H H—C - H H - C - H H—C - 0H H—C—OH H—C—H H - C—H CH3 CH3 CH3 CH3 CH2OH CH20H. . For greater certainty and without limitation , in particular embodiments any one or. more compounds in the deiinition oi tetrose may be exc|uded and in particular. embodiments such exc|uded tetroses may be or may comprise one or more oi. threonate , erythrose - 4aphosphate , acetoacetate , sodium butyrate , succinic acid , . and D - beta - hydroxybutyrate. |t wiI| be understood that the tetrose used in particu|ar embodiments may be used. in combination with suitab|e pharmaceuticalIy acceptab|e carriers 0r excipients and may be used in any suitable dosage iorms. Those skiIIed in the art wiII readin identiiy , seIect irom , and use the ioregoing to suit the circumstances in question. 1O. 15. 2O. 25. 3O. WO 2010 / 043029 PCT / CA2009 / 001440. Where the ce|I to be treated is comprised in the body oi a subject the methods discIosed may be imp|emented and the compositions discIosed may be deIivered to the ce|| in any conventionaI ways incIuding without Iimitation the de|ivery oi the tetrose or prodrug , orally , parentaI|y , enteraIIy , intramuscu|ar|y , subcutaneoust , intravenously , or by inha|ation and may be deIivered in combination with suitabIe carriers or excipients , in suitable dosage forms incIuding without Iimitation tablets , capsules , subdermal pumps or other routes useiu| to achieve an eiiect. AIternative deIivery methods may incIude osmotic pumps , impIantable infusion systems , intravenous drug de|ivery systems , and refiIlab|e imp|antab|e drug delivery systems. DeIivery by inha|ation may comprise deIivery using nebu|izers , metered dose inhalers , powder inha|ers , aII oi which are iamiliar to those skiI|ed in the art. SuitabIe methods , compositions and routes oi deIivery wiII be readily recognised and implemented by those skiI|ed in the art. Embodiments : . First embodiment : In a first embodiment there is discIosed a method ior inhibiting the growth oi cancer cel|s comprising direct|y or indirectIy exposing said cancer celIs to a pharmaceuticaIIy eiiective concentration of tetrose. ln embodiments the tetrose may be or may comprise erythrose , erythru|ose or threose , and in selected embodiments may be or may comprise D - erythrose , L - erythrose , D - threose , L - threose , D - erythrquse , L - erythrquse , and in particu|ar exampIes the tetrose may. be D—erythrose , D - threose , or L - erythru|ose In aIternative embodiments there is disclosed the use oi tetrose to inhibit the growth oi cancer celIs. In embodiments ce|ls may be exposed to the tetrose at a concentration oi irom at I Ieast about 100mg / Iitre up to about 1000 mg / Iitre or more. In aIternative embodiments the cel|s may be exposed to the tetrose at a concentration oi at. Ieast about 100 mg / Iitre , or at Ieast about 200 mg / litre , at |east about 300 mg / |itre , at |east about 400 mg / |itre , at Ieast about 500 mg / Iitre , at |east about 600 mg / Iitre , at least about 700 mg / |itre , at |east about 800 mg / |itre , at |east about 900 mg / |itre , at |east about 1000 mg / litre or more. |n embodiments the tetrose may be appIied to ceIIs under conditions where the ceI|s are simuItaneous|y exposed to qucose at. 17. 1O. 15. 20. 25. 30. WO 2010 / 043029 PCT / CA2009 / 001440. a concentration oi greater than about 600 mg / litre , greater than about 700mg / litre , greater than about 800mg / Iitre , greater than about 900mg / Iitre , or greater than about 1000mg / Iitre. |n one aIternative embodiment the tetrose may be D - erythrose , which may be used at a concentration oi between about 200mg / |itre and about 1000mg / |itre or between about 50O mg / Iitre and about 1000mg / Iitre. |n. embodiments the D—erythrose or other tetrose may be used at concentrations above 1000mg / Iitre. It wi|| be understood that the speciiic dosage desirabIe or suitab|e wil| vary depending on a variety oi iactors inc|uding but not Iimited to the disease to be treated , weight , sex , metaboIism oi the subject and the speciiic tetrose or composition being appIied. Where the tetrose is D - erythrose andis appIied at a concentration oi between about 200 mg / Iitre and about 1000mg / Iitre , then in some cases an accompanying g|ucose concentration of greater than about 50O mg / Iitre , 600mg / litre , 700 mg / |itre , 800mg / |itre , 900mg / Iitre or greater than about 1000 mg / |itre may be required in order to obtain a desired efiect on ceIl growth. |n particuIar embodiments lower glucose |eve|s or more severe|y Iimited avaiIabi|ity. of qucose or energy suppIy may require increased Ieve|s oi tetrose to inhibit the growth oi cancer ceIls. In particuIar embodiments an eiiective dose oi a seIected tetrose may comprise up to about 0.1 gram oi tetrose per kg body weight oi a subject or may comprise up to about 0.5g / kg body weight of the subject , up to about 1g / kg body weight oi the subject or up to about 2g / kg ; or up to about 3g / kg , or up to about 4g / kg , or up to about 59 / kg , or up to about 10g / kg body weight of the subject , or more. In embodiments an eiiective dose oi a selected tetrose may comprise up to about O.5g , 1.0g , 1.5g or up to about 2.0g of tetrose per kg body weight oi a subject. In aIternative embodiments the tetrose or combination thereof may be administered in a sqution oi up to about 1% or up to about 2% , 3% , 4% , 5% , 6% , 7% , 8% , 9% , 10% , 11% , 12% , 13% , 14% , 15% , 16% , 17% , 18% , 19% , 20% , 21% , 22% , 23% , 24% , 25% , 26% , 27% , 28% , 29% , 30% , 35% , 40% , 45% , 50% or greater than about 50% concentration by weight. |n embodiments the tetrose or combination thereoi may be administered in a so|ution containing up to about 16% to 40%. 18. 1O. 15. 2O. 25. 30. WO 2010 / 043029 PCT / CA2009 / 001440. tetrose. |n aIternative embodiments the compositions may be administered to a subject continuous|y , once a day , twice a day , three times a day , iour times a day , at ieast about once an hour , or more or less irequentIy. In embodiments the tetrose may be administered to a subject twice a day or three times a day. In embodiments the tetrose may be administered at least about 1 , 2 , 3 , 4 , 5 , 7 6 or more times a day , or at |east 1 , 2 , 3 , 4 , 5 , 6 or more times a week , and may be administered alone or in combination with other active or inactive agents. In. embodiments the tetrose may be administered to a subject for 1 , 2 , 3 , 4 , 5 , 6 or more days continuously. In aIternative embodiments of the iirst embodiment , the tetrose may be selected irom the group consisting oi erythrose , threose and erythru|ose and isomers thereoi. |n iurther aIternative embodiments oi the iirst embodiment indirect exposing may comprise administering a prodrug. In a|ternative embodiments the cancer cells may be exposed to a concentration oi greater than about 100mg / |itre , 200mg / litre , 300 mg / |itre , 400mg / Iitre , 500mg / Iitre , 600mg / Iitre , 700mg / Iitre , 800mg / litre , 900mg / Iitre or more than about 1000 mg / Iitre oi tetrose , or may be exposed to a glucose concentration oi greater than about 500 mg / |itre beiore or simuItaneous with said exposure to tetrose. Second embodiment : In a second embodiment there is disclosed a method ior improving the viabi|ity oi a ceI| , the method comprising direct|y or indirectIy exposing said ceI| to a therapeuticaHy eiiective amount of tetrose. There is aIso disclosed the use oi tetrose ior improving the viability of a ce|l. ln embodiments the cell may be unable to use g|ucose to maintain ceIl viabi|ity , or may be subject to conditions oi Iow energy supp|y or g|ucose or energy deiiciency or may have a mitochondrial disorder. |n iurther embodiments there is discIosed a method oi treating a mitochondriaI disorder or compensating the energy deiiciency in a celI. comprising directly or indirect|y supplementing the nutrient suppIy to said ce|I with an eiiective dose oi tetrose. Tetrose may be an eiiective energy source ior mammalian ceIls under conditions wherein the cel|s are unable to use g|ucose to maintain celIuIar functions. SuitabIe. 19. 1O. 15. 2O. 25. 30. WO 2010 / 043029 PCT / CA2009 / 001440. conditions ior the use oi tetrose as an energy source ior ceIIs may inc|ude conditions wherein the ceIIs are unab|e to use g|ucose eificient|y , such as mitochondriaI deiiciency / dysfunction , iniection with virus or bacteria , or other medica| conditions resuIting in |ow ceIIu|ar energy generation or abnormaI ceI|uIar energy generation , including without Iimitation extreme high anaerobic egco|ysis. In particuIar embodiments the tetrose may be or may comprise erythrose , erythru|ose or threose , and in se|ected embodiments may be or may comprise D— erythrose , L - erythrose , D - threose , L - threose , D - erythrquse , L - erythrquse , and in particu|ar examples the tetrose may be D - erythrose or L - erythru|ose. |n particuIar embodiments the tetrose may be D - erythrose and may be applied to the ceIls at a concentration oi about 1 - 200 mg / |itre and may be appIied at concentrations of up to about 20 mg / litre , up to about 40 mg / Iitre , up to about 60 mg / |itre , up to about 80 mg / litre , up to about 100 mg / Iitre , up to about 200 mg / litre , up to about 300 mgllitre , up to about 400 mg / litre , up to about 600 mg / Iitre , up to about 800 mg / Iitre , up to about 1000mg / litre or more than about 1000mg / Iitre. |n aIternative embodiments the ceI|s may be exposed to tetrose at any concentration and in any iorm suificient to adjust the ATP or pH homeostasis oi the targeted ce|Is to support ceIIuIar iunction , which concentrations and iorms wilI be readin determined by those skiIIed in the art using known procedures. In embodiments improving the viabiIity of ce||s may comprise improving mitochondriaI iunction in the ce||s , which may be achieved by exposing the ce|Is to tetrose in combination with other pharmaceutically active compounds that wiI| be readi|y identiiied , seIected irom and uti|ised by those ski|Ied in the art. |n particuIar embodiments tetrose may be delivered or used in combination with one or more compounds that may incIude but are not Iimited to DCA ( dichIoroacetate ) , ginkgo biIoba extract , hydroxytyrosol , and resveratroI. |n a|ternative embodiments oi the second embodiment the ce|| may be exposed to conditions oi energy Iimitation. ln aIternative embodiments oi the second embodiment the ceII may have a mitochondriaI disorder. In aIternative embodiments tetrose may be se|ected irom the group consisting oi erythrose , threose and erythrquse. ln a|ternative embodiments of the second embodiment. 20. 10. 15. 20. 25. WO 2010 / 043029 PCT / CA2009 / 001440. the method may comprise exposing said ceIls to a concentration oi between about 1 mg / |itre and about 1000 mg / Iitre oi tetrose. |n embodiments the method may comprise exposing the ceIIs to a concentration oi between about 1 mg / Iitre and about 200 mg / litre oi tetrose. In aIternative embodiments oi the second embodiment the mitochondrial disorder may be associated with a disorder selected irom the group consisting of neurodegenerative disease AIzheimers disease , Parkinson ' s disease , Huntington ' s disease , cardiovascular disease , stroke , obesity , diabetes , multiple scIerosis , systemic |upus erythematosis , rheumatoid arthritis , schizophrenia , bipolar disorder , depression , ataxia , autism , epi|epsy , migraine , Batten disease , Lactic acidemia , Lebers disease , mitochondria| cardiomyopathy and myopathy , parap|egin , NASH , and WiIsons disease. In a iurther a|ternative embodiment oi the second embodiment there is discIosed a method oi treating a mitochondria| disorder in a subject having such disorder , the method comprising direct|y or indirectly administering to the subject an eifective dose oi tetrose. m a further embodiment there is disclosed the use oi tetrose to treat a mitochondrial disorder , or to treat other medical conditions which may include without limitation conditions oi energy deiiciency. Third embodiment : . In a third embodiment there are disc|osed compositions comprising a pharmaceuticaIIy acceptabIe carrier or diIuent and a direct or indirect sources oi tetrose in amounts efiective to inhibit the growth oi a cancer ce|| or to increase the. viabi|ity oi a ceIl under conditions oi low energy suppIy ; or to increase the viabiIity oi a ceI| having a mitochondriaI disorder. In alternative embodiments there is discIosed a composition comprising : a direct or indirect source oi tetrose in an amount effective to inhibit the growth oi cancer celIs ; and a pharmaceuticaIIy acceptable carrier or di|uent. In alternative. embodiments the compositions discIosed may comprise a direct or indirect source. 21. 10. 15. 2O. 25. WO 2010 / 043029 PCT / CA2009 / 001440. oi tetrose in an amount eiiective to increase the viabi|ity oi a ce|I having a mitochondriaI disorder ; and a pharmaceutical|y acceptab|e excipient. Fourth embodiment : . In any embodiment there are disclosed compositions comprising a prodrug metaboIisabIe to yieId a pharmaceutica|Iy eiiective amount oi tetrose. ln aIternative embodiments there are discIosed compositions comprising a prodrug metaboIisabIe to yield a pharmaceutical|y eiiective amount oi tetrose and in alternative embodiments there is disclosed the use oi the prodrug to manuiacture a dietary supp|ement , to inhibit the growth of cancer ce||s ; to increase the viabi|ity. oi cel|s under Iow energy conditions ; and to increase the viabi|ity of ceI|s having a mitochondrial disorder. ln aIternative embodiments there is disclosed the use oi an efiective dose oi a prodrug metaboIisable to yieId tetrose to achieve an eiiect seIected irom the Iist consisting oi : inhibiting the growth of cancer cel|s ; increasing the viabi|ity of ceI|s under low energy conditions ; and increasing the viabiIity oi ce|Is having a mitochondrial disorder. In a|ternative embodiments there is disc|osed the use oi a tetrose containing prodrug to manuiacture a dietary supplement. In embodiments the prodrug may be or may comprise heptose , may comprise a monosaccharide. having the moIecuIar iormula C7H14O7 and may comprise sedoheptquse , mannoheptulose , vitamin C or ascorbate. Fiith embodiment : . In an embodiment there are disc|osed methods oi increasing the viabiIity oi a ceIunder Iimited energy supply and methods oi inhibiting the growth of a cancer ce|I. The methods may comprise direct|y or indirectly exposing the ceII to tetrose in the presence of compounds known to enhance intrace|lu|ar carbonic anhydrase activity or otherwise modulate ceI|u|ar or extraceIIuIar enzymes. |n embodiments the compound may be or may comprise a pharmaceutica|Iy acceptabIe zinc sa|t which may be zinc Chloride , zinc suliate , zinc acetate , zinc monomethionine , zinc quconate , a zinc saIt oi an amino acid , such as : zinc qutamate , zinc aspartate , a. 22. 1O. 15. 2O. 25. WO 2010 / 043029 PCT / CA2009 / 001440. zinc saIt oi an organic acid , such as zinc oxa|oacetate , zinc ma|ate , zinc iumarate , zinc succinate , a zinc salt oi a monosaccharide acid , zinc ascorbate , or in any other iorm readi|y taken up by a ceI| , aI| oi which wi|| be readi|y identiiied , understood , seIected irom and utiIised by those skiI|ed in the art. ln embodiments ceI|s may be exposed to the zinc at a concentration oi from at Ieast about 5pM , 10pM , 15pM , 20pM , 25pM , 30pM , 35pM , or more up to about 40pM or more. Suitable concentrations wi|| be readin identiiied , seIected irom and utiIised by those ski|led in the art. Sixth Embodiment : . In an embodiment there are disc|osed methods oi increasing the viability of a ceII under limited energy supp|y and methods oi inhibiting the growth oi a cancer ceII. The methods may comprise directly or indirectly exposing the ceI| to tetrose in the presence oi compounds known to inhibit extraceI|uIar carbonic anhydrase activity. ln embodiments the compound may be or may comprise quaternary ammonium su|iani|amide , or may comprise other suitab|e carbonic anhydrase inhibitors , aII oi whichwiII be readi|y identiiied , seIected irom and used by those skiI|ed in the art. |n embodiments the carbonic anhydrase inhibitor may be a compound to which the ce|| membrane is partiaI|y or whoIIy impermeable. Where the compound is ammonium suIianiIamide it may be provided to a subject in amounts oi irom 125mg to 1000mg one to four times a day. Seventh Embodiment : . |n an embodiment there are disclosed methods oi increasing the viabi|ity oi a ceIl under Iimited energy suppIy. The methods may comprise direct|y or indirectIy exposing the ceIl to tetrose in the presence oi a compound or composition known to enhance mitochondrial iunction. In particular embodiments these may be or may comprise without |imitation dichloroacetate , ginkgo biloba extract , hydroxytyrosoI , reservatrol , ascorbic acid , ascorbate. A wide range oi suitab|e. compounds and preparations wiI| be readi|y recognised , seIected irom and used by those skiIled in the art. 23. 10. 15. 2O. WO 2010 / 043029 PCT / CA2009 / 001440. EXAMPLES. The ioIIowing exampIes are presented ior the purpose oi iIlustrating embodiments and are not |imiting. Methods. CeIl Culture : CeII Iines are cultured in ceI| cu|ture incubator in media oi DMEM or RMPl1640 with diiierent concentrations of qucose , D - erythrose , L - erythrulose , D - threose , ZnCI2 and 10% FBS. Trypan - BIue assay : CeII number and viabiIity was determined using a standard Trypan - B|ue assay counted on a hemocytometer. MTT assay : It measures the specia| activity oi mitochondria to cIeave the tetrazoIium ring oi the so|ub|e dye 3 - ( 4 , 5 - dimethylthiazol - 2 - yl ) - 2 , 5 - diphenyltetrazolium bromide ( "MTT" ) to diiierentiate |ive cells from dead ce||s. Media ior adherent ceI|s is washed beiore MTT assay. The MTT assay is based on the production oi a dark que iormazan product by active dehydrogenase in the mitochondria oi Iive ceIIs. The numbers oi live cells ( ceII pro|iieration ) , or the. mitochondria activity oi |ive ceI|s , can be measured by absorbance oi visibIe |ight by the iormazan at 595 nm. ExampIe 1 : D - Erythrose inhibits cancer ceII growth. ExampIe 1.1 : MCF - 7 ( Human breast adenocarcinoma ceII |ine ) was cultivated with. diiferent concentrations oi D - erythrose in 1g / L glucose DMEM media ior 24 hours. Live and dead celIs were counted with Trypan - Blue assay ( Table 1.1 ) . TabIe 1.1 : Live and dead ceIl percentage with diiierent D - erythrose concentration. . . . . . . . . . . . . D - erythrose. ( mg / L ) 1 O 50 1 00 200 300 400 Iive Idead |iveIdead live dead live Idead Iive Idead Iive Idead. MCF - 7 9a1 1.9I99 - 4 o. e , 99.4 o.6.1oo. oI o. oj1oo. oI o. oI55.4 44.6j. . . . . 24. 1O. 15. WO 2010 / 043029 PCT / CA2009 / 001440. Examp|e 1.2 : Mouse Lung Carcinoma ( LL2 ) was cultivated with diiferent concentrations oi D - erythrose and glucose ior 48 hours in DMEM media. Live ceII percentage was counted with Trypan - BIue assay ( Tab|e 1.2a ) , 0 mg / L D - erythrose was 00ntroI at 100%. Lower concentration had no eiiect in ceI| death ; ceII pro|iferation was inhibited with increasing concentration oi D - erythrose. Cell proIiferation based on mitochondria activity was measured by MTT assay ( Tab|e 1.2b ) . CeI| proIiieration decreased with increasing D - erythrose. Table 1.2a : Live cell comparison oi LL2 with diiierent D - erythrose and qucose concentration ior 48 hr. . . . . . . . . D - erythrose ( mg / L ) 0| 10| 25 50| 75 100I 150I 25oI 500 Media\ Live CelI Comparison. 1g / L qucose 100% 10o% 100% mm 100% 10o%I 95% es%l 30% 2g / L g|ucose 100% 100% , 1o0% 100% 100% 1oo% 95% 85%I 30%. 4g / L qucose 100% 100%I 100% 10o% 100% 100% 95%l 85%I 30%I. . . . . . . . . Table 1.2b : CeII proIiieration oi LL2 with diiierent D - erythrose and qucose concentration ior 48 hr. . D - erythr0se ( mg / L ) OI 10 25 50 75 100 150 250 50OI , 1g / L 1.51 1.77 1.83 1.80 1.87 1.76 1.77 1.61 1.13 |ucose ( i0.16 ) ( : t0.13 ) I ( : I : 0.02 ) ( i0.28 ) ( : l : 0.16 ) ( : l : 0.41 ) ( : 0.19 ) ( : I : 0.15 ) ( : I : 0.31 ) 2g / L 1.58 1.50 1.48 1.62 1.33 1.62 1.56 1.36 0.74 quc0se ( i - 0.58 ) ( i0.09 ) ( i0.13 ) ( : t0.33 ) ( i0.37 ) ( : I : 0.36 ) ( : 0.39 ) ( : 0.38 ) ( + _ - 0.25 ) 4g / L 1.59 1.49 1.52 1.48 1.42 1.43 1.49 1.51 . o_97 qucose ( : O.18 ) ( w.07 ) ( : 0.03 ) ( : 0.06 ) ( i0.12 ) ( i0.22 ) ( : 0.08 ) ( : 0.13 ) ( : 0.09 ) . . . . . . . . . . . . . . . . ExampIe 1.3 : Human colorectal cancer ceII |ine ( SW480 ) was cuItivated with diiferent concentrations of D - erythrose in 1g / L qucose DMEM media for 48 hours and m0use colon cancer cell Iine ( CT26 ) was cu|tivated with difierent concentrations oi D - erythrose in 1g / L qucose RPMl1640 media ior 48 hours. CeII. proliferation based on mitochondria activity was measured by MTT assay ( Table 1.3 ) . 25. 1O. 15. WO 2010 / 043029. PC T / CA2009 / 001440. Tab|e 1.3 : CelI proliieration oi SW480 and CT26 with D - erythrose in 1g / L g|ucose. . . . media ior 48 hr. D - . erythrose 0|. ( mg / L ) 0 10 25 50 75 10 15o 250 500I sw4e0 0.65 0.68 0.67 0.7 0.71 o.66l 0.68 0.54 0.15 In DMEM ( 10.02 ) ( : 005 ) ( : 0.07 ) ( : 0.07 ) ( a0.0s ) ( ao.03 ) ( : 0.03 ) ( a0.07 ) ( a0.00 ) CT26 in. RPMI 0.6 0.58 o.53. 0.56I 0.57 0.55 0.49I 0.41 0.13 1640 : 0.01 ) ( : 0.03 ) ( : 0.14 ) ( : 0.01 ) ( a0.02 ) ( a0.04 ) ( a0.05 ) ( : 0.00 ) ( : 0.03 ) . . . . . . . . . . . . . Example 1.4 : Mouse c0Ion cancer ceI| Iine ( CT26 ) was cuItivated with diiferent concentrati0ns oi D - erythr0se in 1g / L qucose DMEM media ior 24 or 48 hours. Cell proIiieration based 0n mitochondria activity was measured by MTT assay ( Table 1.4 ) . Tab|e 1.4 : CelI proIiieration oi CT26 with D - erythrose in 1g / L DMEM media for 24. . . . or 48 hr. D - erythrose I I. ( mg / L ) 0 25 50 75 100 150 250 500 o.76 0.7eI 0.76 0.73 0.77 0.68 o.11. 24hr ( : 0.02 ) . ( a0. o2 ) ( : 0.04 ) ( a0.02 ) ( a0. o2 ) ( : 0.03 ) ( : 0.01 ) 0.8I o.71 o. o.68. 0.66 0.5e 0.54 o.16. 48hr ( a0.00 ) . ( a0.11 ) ( a0.04 ) ( a0.04 ) ( : 0.05 ) ( a0.02 ) ( a0.00 ) ( a0.02 ) . . . . . . . . . . . Examp|e 1.5 : With difierent concentrations oi glucose and D - erythr0se in DMEM tissue culture media , three ceIls |ines in vitro were tested : U87MG , BT474 and. Panc - 1. Aiter 96 hours incubation , no massive adhering ceI| popuIation cou|d be. 0bserved ior alI cancer ceIl Iines under microscopy. Ce|l viabi|ity was determined with Trypan - Blue assay ( TabIe 1.5 ) . TabIe 1.5 : Viabi|ity aiter cu|ture with difierent concentration 01 qucose and D—. erythrose. 26. 10. WO 2010 / 043029 PCT / CA2009 / 001440. . . . . . . . . . . . . . . . . . . Cancer Growth condition ICelI / WeII atICeIlNVeH at Viabi|ity Live celI Ce|I Line the start oi he end of ( % ) number cuIture cuIture change ( % ) g 4.5 g / L glucose 100 , 000I 780 , 000| 92 617.6 g 1.0 g / L qucose + 100 , 00 45 , 000 33.3 - 85.02 a 3.5 g / L D - erythrose 0I I 4.5 g / L D - erythrose 100 , o00| 20 , 000I 66.7 - 86.66 E45 g / L glucose 70 , o00I 435 , 000| 10q 521.43 3 1.0 g / L qucose + 0I 0I 0I —100 3 3.5 g / L D - erythrose 7o , oo 4.5 g / L D - erythrose 70 , 000| 0i 0| —100 E 4.5 g / L glucose 30 , o0o| 85 , 0oq 100| - 6.25 ii 10 g / L glucose + 0I - 100 m 3.5 g / L D - erythrose 30 , oo 4.5 g / L D - erythrose 30 , o0oI q o| - 100|. . . Example 2 : Zinc enhance D—Erythroses abiIity oi inhibiting cancer cel| growth. MCF - 7 ( Human breast adenocarcinoma ce|I line ) was cuItivated with difierent concentrations oi ZnCI2 in 1g / L glucose and 400 mg / L D - erythrose DMEM media ior 24 hours ( Table 2.1 ) . HEL ( Human Erythroleukemia ) was cuItivated with diiierent concentrations oi ZnCl2 and D - erythrose in 1g / L qucose DMEM media ior 24 hours , Iive cel| comparison with 0pM added ZnCI2 as 100% ( Tab|e 2.2 ) . Live and dead cel|s were counted with Trypan - B|ue assay. Tab|e 2.1 : Live and dead celI percentage oi MCF - 7 with diiierent concentration of Zan. . . . . . . . . . . . . . Added ZnCI2. ( UM ) o 3 5 1o 2o 40 Iive dead Iive |dead Iive dead live dead Iive IdeadIiveIdead. MCF - 7 55.4 44.6 56.8I 43.2 230 72. q19.6 , 30.4242 75.3 5.2 94.9. . . . . TabIe 2.2 : Live ceII comparison 0i HEL with difierent concentration oi ZnC|2 and D—erythrose. . D - erythrose ( mg / L ) \Added ZnC|2 ( IJM ) 0I 3 5 10 2d 4d. . 4OO 1 OO% 75% 81 % 82% 52% 48%. . . . . . . . . . 30O 1 OO% 89% 96% 99% 78% 75 %. . 27. 1O. 15. WO 2010 / 043029 PCT / CA2009 / 001440. Examp|e 3 : D - Erythrose enhance ceI| viabi|ity. Mouse Lung Carcinoma ( LL2 ) and mouse colon cancer ceII Iine ( CT26 ) were cultivated with diiferent concentrations oi D - erythrose in |ow glucose ( 0.5g / L ) DMEM media ior 48 hours. Live cel| percentage oi LL2 was counted with Trypan - B|ue assay ( TabIe 3.1 ) , 0 mg / L D - erythrose was controI as 100% ; data oi treatment was comparable result of same glucose concentration. Cell proIiieration based on mitochondria activity was measured by MTT assay ( Tab|e 3.2 ) . In |ow glucose ( 0.5 g / L ) media , D - erythrose increased ceI| viabiIity. TabIe 3.1 : Live cel| comparison oi LL2 ior 48 hr with D - erythrose in 0.5g / L g|ucose DMEM. . . . . . . . . . . . D_ erythrose ( mg / L ) I 0 - 10I 25 50 75 100 150 250 500I LL2 1oo% 120% , 120% , 120% 120% 120%120% 12o% 12o%. . . . Table 3.2 : CeII pro|iieration oi LL2 and CT26 ior 48 hr with D - erythrose in 0.5g / L gluCose DMEM. . . . . . . . . . . . . . D - erythrose. mg / L ) 0 10I 25 50I 100 150. 25o 500 0.27 0.35| 0.36I 0.37 0.43 0.42 0.52 0.4. LL2 ao.03 ) ( 3 : 0.06 ) ( _ + .0.01 ) ( : 0.01 ) ( : 0.01 ) ( : 0.02 ) ( a0.03 ) ( a0.03 ) 0.12 0.17 0.17 0.17 0.15 0.16 0.2 - 0.15. CT26 ( : 0.02 ) ( a0.03 ) ( : 1 : 0.03 ) ( : 0.10 ) ( a0.01 ) ( a0.03 ) ( : 0.02 ) ( : 0.00 ) . . ExampIe 4 : Zinc enhance D - Erythroses abi|ity oi increasing cell viabi|ity. MCF - 7 ( Human breast adenocarcinoma ceIl Iine ) was cultivated with different concentrations oi D - erythrose and Zan in 1g / L g|ucose DMEM media ior 24 hours. Live ce|l percentage was counted with Trypan - B|ue assay ( TabIe 4.1 and Table 4.2 ) . Zinc enhances D - erythroses ability oi increasing ce|I viabi|ity. TabIe 4.1 : Live ce|l percentage oi MCF - 7 with difierent concentrati0n oi ' D - erythrose and ZnCl2 compare t0 0mg / L D - erythrose. 28. 1O. 15. . . . . . W0 2010 / 043029 D - erythrose ( mg / L ) \ Added anI2 ( pM ) 5 10 20 4o 10O 1O6° / oI128% 137% 1 1 0% 50 116%139%131%i121% 10 131° / o142%107° / o131% 0 100% 100% 100% 100%. . . . . . . . PC T / CA2009 / 001440. Tab|e 4.2 : Live ce|l percentage oi MCF - 7 with diiferent concentration oi D - erythrose and ZnCl2 compare t0 0 or 1 pM Added ZnCI2. . . . . . . . . . . D - erythrose ( mg / L ) \ Added. ZnC|2 ( pM ) I0 or1 5 10 20 40 100 100%117%124%141%115% 50 100%111%117%117%110% 10 100%126%119% 119%. . . Example 5 : L - Erythru|ose inhibits cancer ceII growth. Mouse Lung Carcinoma ( LL2 ) was cuItivated with diiierent concentrations oi D - erythrulose ior 24 hours in 1g / L glucose DMEM media. Ce|I proIiieration based on. mitochondria activity was measured by MTl ' assay ( Tab|e 5 ) . L - erythru|ose has. anti - cancer eiiect. Tab|e 5 : CeII pr0Iiieration oi LL2 ior 24 hr with L - erythru|ose in 1g / L qucose. . . . . . . DMEM L - erythru|ose. ( m9 / L ) 0 10 2000I 5o00 10000 LL2 0.83 : 1 : 0.01 0.64a0.02 o.54ao.02 . o.53m.04 |0.34 : 0.05. . . . . ExampIe 6 : L - Erythrulose enhance cell viabi|ity. Mouse Lung Carcinoma ( LL2 ) was cuItivated with diiierent concentrations oi D - erythru|ose in Iow glucose ( 0.5g / L ) DMEM media for 24 hr. CeII pro|iieration based on mitochondria activity was measured by MW assay ( Table 6 ) . Table 6 : Ce" proIiferation 0f LL210r 24 hr with L - erythruI0se in 0.5g / L qucose. DMEM. 29. 1O. 15. WO 2010 / 043029 PCT / CA2009 / 001440. . . . . . . . . . L - eryihrul0Se & 1000 & 2000 & 5000 & GIuCoSe ( mg / L ) 0 & 50O 50O 500 500 0 & 1000 LL2 O.56i0.03 O.82 : 0.03 ( O.86i0.17 O.82i0.18 O.73i0.04. . Example 7 : D - threose inhibit cancer ce|l growth. Mouse Lung Carcinoma ( LL2 ) was cultivated with diiierent concentrations 0f D - threose i0r 48 hours in 1g / L qucose DMEM media. Live ceII percentage was counted with Trypan—B|ue assay ( Table 7.1 ) , 0 mglL D - threose was controI as 100%. CeI| proIiierati0n based on mitochondria activity was measured by M ' l ' | ' . assay ( Table 7.2 ) . CeII proliieration decreased with increasing D - threose in 19 / L qucose DMEM media. TabIe 7.1 : Live ceII comparison oi LL2 for 48 hr with ditierent D - threose concentration in 1g / L qucose. . . . . . . . . . . . . . D - threose concentration mg / L ) 0 1o0 150 200 250 300 350 40 450I 500I LL2 100% , 10o% 100%95% 95% 90% , 90% 35% 30% 75%. . . TabIe 7.2 : CeII proIiieration oi LL2 i0r 48 hr with difierent D—thre0se c0ncentration in 1g / L g|ucose. . . . . . . . . . D - threose. concentration OI 500 1000 1500 2000I 2500 : 3000. mm. LL2 1.52 1.04 IO.47 - 0.45 - 0.45 IO.34 0.28 ( : 0.04 ) : 0.07 ) ( 1 : 0.06 ) ( : 0.02 ) ( : 0.01 ) ( : 0.03 ) ( : 0.02 ) . . . . ExampIe 8 : D - Erythrose inhibit tumour growth in mice. Mice with tumours grown irom CT26 ceI| Iine under mice ' s skin were treated with an injection oi 8mg D—erythrose beside the tumour per mouse daily. Comparing to control ( treated with PBS ) , tumour growth rate was decreased by 19.46% in two days by the treatment of D - erythr0se. There was no signiiicant difierence ( <1% ) in weight changes between the treatment group and the control group. 30. 10. 15. 2O. WO 2010 / 043029 PCT / CA2009 / 001440. Another two groups oi mice with tumour were treated with 1 ) an injection 0i 20mg D - erythrose beside the tumour per mouse dain ; 2 ) two injections oi 20mg D - erythrose beside the tumour per m0use dai|y. Tumour growth rate reduced 90% ior group 1. ( Tab|e 8 ) . F0r group 2 , the average tumour size shrank about 50% of the originaI size on day 4 ( six mice in the group , except oi an extreme one , the average tumour size ior other 5 mice shrank 95%. ) . Tab|e 8 : Tumour size ( mm? ) and tumour growth rate with once a day or twice a day 20 mg D - erythrose injection. . . . . . . . . . Day 1 Day 4 Change % Contro| 7.38 : 3.45 47.92 : t10.74 549.66% Once daily 7.94 : I : 1.71 12.31 : I : 16.80 55.01% Twice dai|y 9.48 : 1 : 3.11 4.26 : t9.44 —55.04%. . Examp|es and embodiments not limiting : . The embodiments and exampIes presented herein are il|ustrative oi the general nature 0i the subject matter claimed and are not Iimiting. It wiII be understood by those skil|ed in the art h0w these embodiments can be readily modiiied and / or adapted and / or combined ior various app|ications and in various ways without departing irom the spirit and scope 01 the subject matter discIosed cIaimed. The cIaims hereoi are t0 be understood to include without Iimitation aI| a|ternative embodiments and equivaIents of the subject matter hereoi. Phrases , words and terms employed herein are i||ustrative and are not limiting. Where permissibIe by Iaw , aI| reierences cited herein are incorporated by reierence in their entirety. lt wi|| be appreciated that any aspects oi the diiierent embodiments disc|osed herein may be combined in a range oi possib|e aIternative embodiments , and aIternative. combinations oi ieatures , al| oi which varied combinations oi ieatures are to be understood to iorm a part of the subject matter claimed. 31. WO 2010 / 043029 PCT / CA2009 / 001440. THE EMBODIMENTS OF THE |NVENTION |N WHICH AN EXCLUSIVE PFiOPEHTY OFI PH|V|LEGE |S CLAIMED AFIE DEF|NED AS FOLLOWS : . 1. A method for inhibiting the growth oi a cancer ce|| comprising direct|y or. indirectly exposing said cancer cel| to a pharmaceutically eiiective concentration oi tetrose. 2. The method according t0 claim 1 wherein the tetr0se has a structuraI iormula se|ected irom the group consisting oi : . . . . CaH304 H o H o \ / \ 22 c cH2oH C H— : C—OH lc=o Ho—i : —H H—|C—OH H—I3 - OH H—|C - OH CH2oH |CH2oH |CH2OH C4H504 H 0 H o H o H o H o \c / \ 2 \ . / / \ . / / \ xx I i i i i H — c a=o o=c H - a - oHHo—C—H H_é_0H H—C - OH H - C - OH c=o C=o ( ' 3 I I | | / % CH2OH CH2oH CH2OH CH2OH H o H\ / o H . f \ / O H\ / O H\ / O H\ / O HO —C—H ( I f 8 f H - ( |3 - OH c|3| - 0H HO— ( l3| H—a—oH HO - ( l3— * H é C—OH C—OH C—OH C—OH y \ I I II II o H CH2OH CH2OH CHOH CHOH. . . 32. . . WO 2010 / 043029 PCT / CA2009 / 001440 C4H3O3 H O H O H O H O H O \ i \ ﬂ \ ﬂ \ i \ i C C C C ( |3 H—C—H H—C| —H H—C—OH HO - Ci —H H—C—OH H— - C|3— - OH H— ( ‘i —OH H - —C| ) - —H H - Ci - H H—C—OH CH2OH CiH2OH CH2OH CiH2OH CH3 H O \ i C H—C—OH C|H3 C4H5O3 H\ . / / O H\ ¢O H\ / O H\ ' / O i i i i C=O O=C H—C - H H—C—H mm MM C=o C=o CH2OH CH2OH CH2OH CH2OH H \ / O H\ / O H\ / O H\ / O i i i i H - ( i—H H— ( IJ - H H—C—OH H0—C—H H - Ci3—OH H—C—OH H—C—H H—C—H c A A A / \ / \ / \ / / \ H O O H H O O H H \ / o H\ / O H\ / O H\ / O i i ° ° C< - OH HO—C 444 H. CI II II II II CI - H C|—H Cf - OH ( i - wOH CH2OH CH2OH CH2OH CH2OH. . . . 33. . . wo 2010 / 043029 PCTlCA2009 / 001440 C4H4O4 H o H o H o \ / \ / \ I H o H o C C C \ i \ / I l I i i ° =i <f=0 0=<|3 H - C—OH H—C—OH C=O C=O C=O é é A | l / N / N / N CH2OH cH2oH H o H o H o H o \ / C Ho. c ' ; _. , C=o i / N H o C4H403 H O H O H o \ / \ / \ i H o H o C C C \ xx \ / / I I I 7 ( 3| a=o o =a H—C—H ﬁ=0 0=C| H—C—H H—C— - H C=o C=0 C=o A A g I I / N / N / N CH3 CH3 H o H o H o H o \ n c HHH ci=o i / N H o. . . . . . . . WO 2010 / 043029 PCT / CA2009 / 001440 C4H502 H O O \C / H\ 40 H\ ¢O H\ / H\ / 0 I C C C C H—C|3—H C=o o= ( | : MM , _. , I_ , , MM H— - ( |3—H H - C - H C=O CI.=O C I I | I / \ CH3 CH3 CH3 CH3 H O H O \ / C H - é - H H - cl - H c‘ / / \ O H C4H3o2 H O H 0 H O H O H O H O \ I \ i \ f \ I \ / \ / / ' C C C C C C H. i ' : - oH Ho - < ' ; - H H - é - H H. c ' ; _H H. i ' ~._H aaa H. i ' : - H H - c ' ; - H H - c ' ; . oa H - < ' ; - oH H - 511 a - é - H CH3 CH3 CH3 CH3 CH2OH CH2OH. . and any pharmaceutical|y eiiective derivatives there0i. 3. The method acc0rding to cIaim 2 wherein the derivative is a conjugated , . substituted , ionised , sa|t , isomeric , acid , base , a|dehyde , ketone , aIcoho| , amine , amide , thioI , ring or linear form. 4. The method acc0rding to claim 1 wherein the tetrose is seIected from the group consisting oi erythrose , threose and erythru|ose. 5. The method according t0 c|aim 1 wherein said indirect exposing comprises exposing said cancer ce|l to a pr0drug metaboIisabIe to re|ease tetrose. 35. 10. 15. WO 2010 / 043029 PCT / CA2009 / 001440. 6. The method according to claim 1 wherein said cancer ceII is exposed to a concentration oi greater than about 100 mg / Iitre of tetrose. 7. The method according t0 cIaim 1 wherein said cancer ce|l is exposed to a. glucose concentration oi greater than about 500 mg / litre before 0r simuItaneous with said exposure to tetrose. 8. The meth0d according to c|aim 1 wherein said cancer is seIected ir0m the. group consisting of carcinoma , sarcoma , adenoma , Ieukemia , lymphomas and myeIoma. 9. The method according to cIaim 1 wherein said exposure occurs in combination with exposing said ceIl to a modu|ator oi carbonic anhydrase activity. 10. The method according to claim 9 wherein said modu|ator comprises a Zinc sa|t. 11. A method for improving the viability oi a ce|l , said method comprising directIy or indirect|y exposing said ce|| to a therapeuticaI|y eiiective amount oi tetrose. 12. The method according to cIaim 11 wherein the tetrose has a structuraI iormuIa selected irom the group consisting oi : . . . . C4HaO4 H O H O \ / \ / |C lCH2OH |C H—lC - —OH C=O HO—C—H H—|C - OH H—|C—OH H - —|C—0H CH2OH |CH2OH ICH2OH. . 36. . . . . wo 2010 / 043029 PCT / CA2009 / 001440 c4H504 H o \ y H o H o H o H o c \ . / / \ i \ i \ / I C C _ 9 9 H - C—OH C=o o=C H - C - oHHo—C - H H_é_0H H - é - oH H_é_oH é=o C=o g | I I I / N CH2OH CH2OH CH2OH CH2OH H o H 0 \c / H 0 H 0 H o H o l \ / \ / \ / \ / HO—C—H ( I ( I 8 ? H_ ( ' 3_0H ﬁ - 0H HO—ﬁ H—a—oH HO - C|3 - —H é C—OH C—OH C—OH C—OH ﬂ \ | I II II o H CH2OH CH2OH CHOH CHOH CaHaO3 H o H o H o H o H o \ I \ / \ y \ 22 \ xx i i i ‘i i H—C| : —H H—C - H H—C—OH HO—C—H H—C—OH H—C—OH H—c|—oH H - —C - H H - —C|—H H—C - OH CH2OH c| : H2oH OH2OH C|H2OH CH3 H o \ n C Ho - é - H H - 933. iii C4H5O3 H O H o H O H O \ y \ a \ / \ / i i i i C=o O=C H - C—H H—C—H MM H - é - H é=o C=o CH2OH CH2OH CH2OH CH2oH. . . 37. . . . wo 2010 / 043029 PCT / CA2009 / 001440 H o H 0 H 0 H o \ I \ I \ I \ I C i i i H—C—H H—C - H H— - C— - OH HO—C—H H—C - 0H H - C - OH H - C—H H— ( lJ - H i i i i / N I \ / N I \ H o o H H o o H H O H O H o H o \ I \ I \ I \ I C C c C C|—OH HO—CI C—H H—CI CI—H Cl - H CI - oH CI—OH CH2OH CIH2OH CH2OH C|H2OH c4H404 H O H O H o \ I \ I \ I H 0 H o C C \ I \ I I I I a C a=o 0 =tl : H - C| } - —OH <f=0 0=C|3 H - C—OH H—C—OH C=o C=0 C=o A i g | I / N / N / N CH2oH CH2OH H o H 0 H o H o \ I C Ho—C—H C=o i / N H o C4H403 H o H o H o \ I \ I \ I H o H 0 C C C \ I \ I I I I 33 Cl a=o o =a H—C—H ff=0 0= ( I H - C—H H—C—H C=o C=O C=O é ( , 1 A I I / N / N / N CH3 CH3 H 0 H o H o. . . . 38. WO 2010 / 043029 PCT / CA2009 / 001440. . . . . . H O \ I C H - é - H C=o é / N H O C4H502 H O H O \C / H\ IO H\ IO \ I H\ / O I I I I C H ' I H C=0 O=C H—C—H H—O—H H—C—H MM - é - H ( i=o ( i=0 3 | I I I / N CH3 CH3 CH3 CH3 H O H O \ I C H - é - H mm c ' I \ O H C4Ha02 H O H O H O H 0 H O H O \ I \ I \ I \ I \ I \ I C C C C C C H—C—OH HO - C—H H—C—H H—C—H H - C—H H——C—H H - — ( |3—H H—C—H H - C—OH H—C—OH H—C—H H—C - H CH3 CH3 CH3 CH3 CH2OH CH2OH. . and any pharmaceutica|Iy efiective derivatives thereof. 13. The method according to claim 12 wherein the derivative is a conjugated , . substituted , ionised , saIt , isomeric , acid , base , a|dehyde , ketone , alcoho| , amine , amide , thi0I , ring or Iinear iorm. 39. 1O. 15. 2O. 25. WO 2010 / 043029 PCT / CA2009 / 001440. 14. The method according to cIaim 11 wherein said exposure occurs in combinati0n with exposing said cell to a modulator oi carbonic anhydrase activity. 15. The method according to c|aim 11 wherein said ceII is under conditions oi Iimited energy suppIy. 16. The method according to cIaim 11 wherein said ceII has a mitochondriaI disorder. 17. The meth0d according to claim 11 wherein the tetrose is selected irom the group consisting oi erythrose , threose and erythrquse. 18. The meth0d according to claim 11 wherein said indirect exposing 00mprises exposing said celI to a prodrug metabolisabIe to re|ease tetrose. 19. The meth0d according to cIaim 11 comprising exposing said ceIIs to a concentration oi between about 1 mg / |itre and about 200 mg / Iitre oi said tetrose. 20. The method according to cIaim 16 wherein said mit0chondriaI disorder is associated with a disorder se|ected from the group consisting oi neur0degenerative disease , Alzheimer ' s disease , Parkinsons disease , Huntingtons disease , cardi0vascular disease , stroke , obesity , diabetes , muItip|e scIerosis , systemic |upus erythematosis , rheumatoid arthritis , schizophrenia , bipolar disorder , depression , ataxia , autism , epi|epsy , migraine , Batten disease , Lactic acidemia , Lebers disease , mitochondriaI cardiomyopathy and myopathy , parapIegin , NASH , and Wilsons disease. 21. A method oi treating a mitochondrial disorder in a subject having such disorder , said method comprising direct|y or indirect|y administering to the subject a pharmaceutica|ly eiiective dose of tetrose. 22. The method according to cIaim 21 wherein the tetrose has a structuraI iormuIa seIected irom the group consisting oi : . 40. WO 2010 / 043029 PCT / CA2009 / 001440. . C4HaO4 H 0 H O \ I \ I C CH2OH C a - E - oH C=o Ho - E - H. H - : C—OH H— : C - OH H— : C - OH. . . CH2OH CH2OH CH20H C4H5O4 H O \ I H O H O H O H 0 C \ I \ I \ I \ I I i i i i c=o o=c H—C—OHHO—C—H H—C - OH H_i - oH H - i - oH é=o C=o i | I | I / N CH20H CH2OH CH2OH CH2OH H o H O \C / H O H O H o H o I \ I \ I \ I \ I HO — C — H ( I I 8 ? H—C - OH ( |3l—OH HO - ( l?|. H— ( f - OH Ho—c—H é C—OH C— - OH C - 0H C—OH I \ | I II II 0 H CH2OH CH2OH CHOH CHOH C4HaO3 H O H O H O H O H O \ I \ I \ I \ I \ I C C C C C. H—C : : —H H—CI—H H—C| - - OH Ho—ci—H H—C—oH H—a—oH H—CI - OH H—C—H H—C!—H H—C—OH cH2oH Cl‘H2OH CH2OH cIH2oH CH3. H o \ I C HO—C—H H—C—OH ém. . . . 41. WO 2010 / 043029 PCT / CA2009 / 001440. . . C4H6O3 H\ I0 H\ IO H\ Io H\ IO C C C C C=o o=C mm mm mm H - i_H é=o C=o CH2OH CH2OH CH2OH CH2OH H\ IO H\ IO H\ I0 H\ IO i i i i H - ( f—H H— ( |3 - H H - C - OH HO—C—H H—C—OH H— - C—OH H—C—H H—C—H A i i i / N I \ / N I \ H o 0 H H 0 0 H H\ I0 H\ I0 H\ IO H\ I0 I I I I mm mm III H_c ' M M La 33 CH2OH ClH2oH CH2OH OH2OH CaH404 H O H O H O \ I \ I \ I H o H 0 C C C \ I \ I I | | C C C=O O =Cl3 H - C|3 - OH <|3=0 O= ( l3 H—C - —OH H—C—OH C=O C=O C=O C C C | I / N / N / N CH2OH CH2OH H 0 H 0 H O H O \ I C Ho - é - a 0=o é / N H O. . . . 42. . . W0 2010 / 043029 PCT / CA2009 / 001440 CaH4O3 H 0 H 0 H o \ I \ I \ I H O H O C C C \ I \ I I I I a a a=0 =a H—a—H C|3=0 0=CI H—C - H H—C - —H C=O C=O C=O C O C I I / N / N / N CH3 CH3 H 0 H 0 H 0 H 0 \ I C H. c‘ - H c|=o c ' / N H o C4H5O2 H O H O \C / H\ IO H\ IO \ I H\ / / O i ii <|3 ﬁ c H - - C—H $=0 0= ( |3 H - C - H H - C| - H H - c| : - H H—C—H - C - H C=0 ci=0 C I | | | / N CH3 CH3 CH3 CH3 H 0 H 0 \ I C I H—C—H H—O—H c ' I \ o H. . . . 43. 1O. 15. . . W0 2010 / 043029 PCT / CA2009 / 001440 C4H3O2 H O H O H O H O H O H O \ I \ I \ I \ I \ I \ I C C C C C Cl : H—C~OH HO—C—H H—C - H H—C—H H— ( |3—H H—CI3 - H H - C—H H—C—H H—C—OH H— ( : 3—OH H— ( |3 - H H— ( l3—H CH3 CH3 CH3 CH3 CH2OH CH20H. . . and any pharmaceuticalIy effective derivatives thereoi. 23. The method according t0 cIaim 22 wherein the derivative is a conjugated , substituted , ionised , saIt , isomeric , acid , base , aIdehyde , ketone , aIcohoI , amine , amide , thioI , ring or linear iorm. 24. The method according to cIaim 21 wherein the tetrose is seIected irom the group consisting of erythrose , thre0se and erythru|ose. I. 25. The method according to claim 21 wherein said exposure cccurs in combination with exposing said ceII to a modu|ator oi carbonic anhydrase activity. 26. A comp0sition comprising : . a direct or indirect source oi tetrose in an amount eiiective to inhibit the growth oi a cancer ceII ; and. a pharmaceutically acceptable carrier or di|uent. 27. A composition comprising : . a direct or indirect source of tetrose in an amount eiiective to increase the viabi|ity 01 a ce|l having a mitochondriaI disorder ; and. a pharmaceutically acceptable carrier or di|uent. 28. The use oi an efiective dose oi a direct or indirect source 0i tetrose to achieve an eiiect seIected irom the group consisting oi : . 44. WO 2010 / 043029 PCT / CA2009 / 001440. inhibiting the growth oi a cancer ceI| ; increasing the viabiIity oi a cel| under |ow energy conditions ; and increasing the viabiIity oi a ceI| having a mitochondrial disorder. 29. The use according to c|aim 28 wherein the tetrose has a structural iormuIa selected from the group consisting oi : . . . . C4HaO4 H o H o \ I \ I I0 chon |c H - C - OH c=o H0 - C—H H - i : —oH H—|C - OH H——|C—OH IcH2oH |CH20H |cH2oH CaH5O4 H o \ I H o H o H o H o c \ I \ I \ I \ I I i i i i “ - C ' °“ a=o o= ( | : H—a—oH HO—C - H H—C| ) - OH H—C—OH H - C—OH c=o C=o II | I I I / N CH2OH CH2OH CH2OH CH2OH H o H o \c / H 0 H O H 0 H o | \ I \ I \ I \ I HO - C—H I ( I ‘I ? H_ , ' 3_0H II_OH HO_ ( |I H—C|J—OH HO— ( |3 - H é C—OH C—OH C—OH C—OH I \ I I II II o H CH2OH CH2OH CHOH CHOH. . . 45. WO 2010 / 043029 PCT / CA2009 / 001440. . H - C—H H—C—H H—C - —OH HO—Ci - H H—C|7—OH H—C%—OH H—C%—0H H - C : I——H H—C| - H H— ( i‘ , —OH. . . CH2OH CH2OH CH2OH CH2OH CH3 H O \ I C HO _ I - H H - I —OH c ' H3 C4H503 K J , " “\ / ° H\ I0 H\ I0 c c c c l l l l C=O O=C H—C - H H—C—H H - ( l3—H H— ( |J—H c ' ; =o < : : =o CIH2OH ( I3H2OH ( .1 , H2OH CH20H H O H O H 0 H 0 \ I \ I \ I \ I C C C C. H—C|J—H H< ( !3—H H— ( g - OH HO - —Cl—H H— ( %—OH H—C : 3 - OH H— ( %—H H—C : I—H. . . / \ I \ / N I \ H o o H H o o H H 0 H 0 H o H o \ I \ I \ I \ I ‘i a C C C—OH HO—C ( l , _H H_c , l h h ( Ia. ta cH2oH c|H20H cH2oH C|H2OH. . 46. . . wo 2010 / 043029 PCTlCA2009 / 001440 C4H404 H O H O H o \ I \ I \ I H 0 H 0 C C c \ I \ I I I I ‘i ? ff=0 0 = ( |3 H - C—OH <f=0 O=$ H—C - —0H H—C—OH c=o c=o c=o é é é CH2OH ( | : H2OH H / \o H / \o H / \o H o \ I c Ho - é. H é=o é / \\ H o C4H4O3 H O H O H o \ I \ I \ I H o H o C c c \ I \ I I l l ‘f ( I <f=O O = ( ‘1 H—C—H <f=0 0=Ci H—C - H H—C— - H c=o o=o c=0 é é é CH3 cIH3 H / \0 H / \0 H / \0 H o \ I c l H—c—H c|=o é / \\ H o c4H602. . . . . 47. . WO 2010 / 043029 PCT / CA2009 / 001440 H O H O \C / H\ I0 \ IO \ I H\ / O | I I I c ( |3=0 = ( |3 H—C— - H H—CI - H H—C|3—H H—C—H —C—H é=O é=O A I I I | / \ CH3 CH3 CH3 CH3 H O H O \ I C H - é - H H - - C|—H A I \ O H. . . . 48. 10. 15. . . W0 2010 / 043029 PCT / CA2009 / 001440 C4H3O2 H O H O H O H O H O H O \ I \ I \ I \ I \ I \ I C C C C C C H—C - OH HO—C—H H— ( |3 - H H - — - Cl3—H H—C—H H—C—H H—C—H H - C——H H—C—OH H - ( |3—OH H—C|3—H H—C—H CH3 CH3 CH3 CH3 CH2OH CH20H. . . and any pharmaceutically eiiective derivatives thereoi. 30. The method according to claim 28 wherein the derivative is a conjugated , . substituted , ionised , sa|t , isomeric , acid , base , aldehyde , ketone , alcohol , amine , amide , thiol , ring or linear iorm. 31. The method according to claim 28 wherein the tetrose is selected irom the group consisting oi erythrose , threose and erythrulose. 32. The use oi tetrose or a prodrug oi tetrose to manuiacture a dietary supplement. 33. A composition comprising a prodrug metabo|isab|e to yie|d a pharmaceutica|ly efiective amount oi tetrose to : . inhibit the growth of a cancer ce|l ; . increase the viability of a ce|l under |ow energy conditions ; and increase the viability of a cel| having a mitochondrial disorder. 34. The composition according to claim 33 wherein the tetrose has a structural formula se|ected trom the group consisting oi : . 49. WO 2010 / 043029 PCT / CA2009 / 001440. . C4HsO4 H O H O \ I \ I C CH2OH C H - E - oH b=o Ho - E - H. H— : C—OH H<— : C - OH H - : C—OH. . . CH2OH cH2oH cH2oH c4Hs04 H o \ I H o H o H o H o c \ I \ I \ I \ I I c c C I H - C—OH c=o o=é H - é—oHHo—c—H H_é_0H H - é - oH H_I ' ~ , - oH M c=o I I I | | / \ cH2oH cH2oH cH2oH cH2oH H o H o \c / H 0 H 0 H o H o I \ I \ I \ I \ I Ho — c — H g ? C|> ( I H_ ( ' : _0H c|—oH Ho—<| : l H - c—oH HO - ( I3— - H é c—oH C - —0H C—OH C - OH I \ I I II II - o H CH2OH cH2oH cHoH CHOH C4HsO3 H o H o H o H o H o \ I \ I \ I \ I \ I c c c c c. H— ( % - H H—C - H H—C , —OH HO—C—H H - ( |3—OH H—C—OH H—CI - OH H—C—H H - C—H H—C—0H CH2OH C|H2OH CH2OH CH2OH CH3 H O \ I C. HO - ( |3— - H H - é , oH ém. . . . 50. WO 2010 / 043029 PCT / CA2009 / 001440. . . . c4Hs03 H\ I0 H\ IO H\ I0 H\ I0 C C C C I I I I C=O O=C H—C - - H H—C—H H—C|3 - H H—Cb - H CI=O C=O CH2OH ( |3H20H CH2OH CH2OH H O H O H 0 H O \ I \ I \ I \ I C C C C | l I I H—C—H H—C— - H H—C - OH H0—C—H H—C— - OH H— ( |3 - OH H—C—H H - ( |3 - —H I I A I / \ I \ / \ I \ H 0 0 H H 0 O H H O H O H 0 H O \ I \ I \ / \ I C C C C é - oH Ho..é III III CI - H ( |3| - H g—0H ( II - OH CH2OH CH2OH ( IH2OH C|. H2OH C4H404 H 0 H O H O \ I \ I \ I H O H 0 C C C \ I \ I | | i ii 33 C=O O = ( |3 H—C—OH <f=O O=<l3 H—C—OH H—C—OH C=O C=O C=O C ( I C l l / \\ / \ / \\~ CH2OH CH20H H O H O H O H O \ I l HO—C—H é=o é / \\ H O. . . 51. . . W0 2010 / 043029 PCT / CA2009 / 001440 C4H403 H O H O o \ I \ I I H O H O C C C \ I \ I l | I C C| C=O =Cl C—H <f=0 0=Ci H—C - —H H—C—H o=o C=O C=O ( ‘1 C C I l / \ / \ \\ CH3 CH3 H 0 H O O H O \ I C H_c ' - H é=o é / \ H O C4H502 O H O C / H\ I0 H\ IO \ I H\ / / O I I I I c C|3=O O= ( |3 H - C—H H—C - H H—Cl3—H H—C— - H —C—H C=O ( I=O C | I I | \ CH3 CH3 CH3 CH3 0 H 0 \ I C H—C—H III A I \ 0 H. . . . 52. 10. W0 2010 / 043029 PCT / CA2009 / 001440. . \I \I \I \I \I \I. H—C—OH H0—C—H H— ( |3—H H - — ( l3—H H— ( l3 - H H—C—H H—C—H H - ( |3—H H - ( l3—OH H—C—OH H— ( : ' J—H H—C : ) - H CH3 CH3 CH3 CH3 CH2OH CH2OH. . . . and any pharmaceutically eiiective derivatives thereof. 35. The composition according to c|aim 33 wherein the derivative is a conjugated , . substituted , ionised , sa|t , isomeric , acid , base. a|dehyde , ketone , alcohol , amine , amide , thiol , ring or linear iorm. 36. The use oi tetrose to manuiacture a medicament ior : a ) inhibiting the growth oi a cancer cell ; or b ) improving the viability oi a ce|l exhibiting a mitochondrial disorder. 37. The use according to any one oi claims 32 , 33 and 36 wherein the tetrose is se|ected irom the group consisting oi erythrose , threose and erythrulose. ‘. 53. . INTERNATIONAL SEARCH REPORT Internati0na1 app1ication No. PCT / CA2009 / 00l440. . . A. CLASSTF1CATION OF SUBJECT MATTER IPC : A6IK 31 / 7004 ( 2006.0l ) , A61K 45 / 00 ( 2006.0l ) , A61P 35 / 00 ( 2006.0l ) . According to International Patent Classiﬁcation ( IPC ) or to both national classiﬁcation and IPC. . B. FIELDS SEARCHED. . Minimum documentation searched ( classiﬁcation system followed by classiﬁcation symbols ) A61K 31 / 7004 ( 2006.01 ) , A61K 45 / 00 ( 2006.01 ) , A61P 35 / 00 ( 2006.01 ) . . Documentation searched other than minimum documentation to the eXtent that such documents are included in the ﬁelds searched A61K 31 / 70 ( 2006.01 ) . . Electr0nic database ( s ) consulted during the international search ( name of database ( s ) and , where practicable , search terms used ) . Canadian Patent Database ; EPOQUE ' , Delphion , PubMed ; Goog1e : tetrose , erythrose / erythronate , threose / threonate , erythrulose | cancer , tumo?r , neoplas * , anti?ne0plas * , Carcinoma , sarc0ma , adenoma , leukemia , lymphoma‘? , myeloma. . C. DOCUh / [ ENTS CONSIDERED TO BE RELEVANT. . Category * Citation of d0cument , With indicati0n , Where appropriate , 0f the re1evant passages Re1eVant to claim No. . X WOOl / l5692 A1 08 March 200l JARTWALLA. Meth0ds and c0mp0siti0nsf0r selecring cancer chem0rherapy. Dl : see pages 13 , 14 - l7 , 2l - 23 , and table l. 26 , 28 — 29 , 33 - 37. TALUKDER er al. , October 2002 , C1in. Cancer. Res. , 8 ( 10 ) : pp. 3285 - 3289. 26 , 28 - 29 , 33 - 37 Antihuman epidemalgmwihfactor recepi0r2 ann ' body herceptin inhibits aut0crine m0tilily facr0r ( AMF ) exprchi0n and p0tentiates antitumm‘ ejﬁ ' cts 0f MF inhibimrs. [ ISSN : 1078 - 0432 ] . http : / / clincancerres. aacri ournals . org / content / 8 / 1 0 / 32 8 5 . ful1. pdf + htm1. D2 : See abstract ; page 3288. . 26 , 28 - 29 , 33 - 37 FAY et al. , NoVember 1994 , Gen. Pharmac. , 25 ( 7 ) , pp. 1465 - 1469. Eﬂcci 0fald0nic acids‘ 0n ihe upiake 0f asc0rbic acid by 3T5 m0useﬁbr0blasts and human lemph0ma celIs. [ doi : 10.1016 / 0306 - 3623 ( 94 ) 90175 - 9 ] [ ISSN : 0306 - 3623 ] D3 : See pagel468. . . . [ X ] Further documents are listed in the continuation of BOX C. [ X ] See patent family anneX. . * Specia1 categories of cited documents : “T” 13ter document pub1ished aﬁer the international ﬁ1in date or priority. date and not in conﬂict with the app11ication but cite to understand the pr1nc1ple or theory underlymg t e 1nvent1on. “A” document deﬁning the general state of the art which is not considered to be of particu1ar relevance “X” document of particu1ar re1evance ; the c1aimed invention cannot be “”E earlier application or patent but published on or aﬁer the international considered novel or cannot be considered to involve an inventive ﬁling date step when the document is taken alone “L” document which may throw doubts on priorig claim ( _s ) or which is “Y” document of particular relevance ; the claimed invention cannot be c1ted to establ1sh the publ1cahon date of ano er c1tat1on or other cons1dered to 1nvolve an mvent1ve step when the document 15 special reason ( as speciﬁed ) combined with one or more other such documents , such combination _ _ _ _ _ being obvious to a person skilled in the art document referrmg to an ora1 d13c1osure , use , eXh1b1t1on or other means ‘ “&” document member of the same patent fam11y “P” document published prior to the internationa1 ﬁ1ing date but later than. the pr1or1ty date cla1med. . Date of the actua1 comp1eti0n of the international search. 28 January 2010 ( 28 - 01 - 2010 ) . Date of mai1ing of the internationa1 search report. 1 February 2010 ( 01 - 02_2010 ) . . . Name and mai1ing address of the ISA / CA Canadian lntellectual Property Ofﬁce. Place du Portage I , C1 l4 - 15t Floor , BOX PCT 50 Victoria Street. Gatineau , Quebec K1A 0C9. Facsimile No. : 001 - 819 - 953 - 2476. . Authorized ofﬁcer. C. Bourque ( 819 ) 934 - 3596. . Form PCT / lSA / 210 ( second sheet ) ( July 2009 ) . Page 3 of 6. . . INTERNATIONAL SEARCH REPORT Internati0na1 app1ication No. PCT / CA2009 / 001440. . . Box N0. 11 Observations Where certain claims Were found unsearchable ( C0ntinuation of item 2 0f the first sheet ) . . This internationa1 search rep0rt has n0t been established in respect of certain claims under Article 17 ( 2 ) ( a ) f0r the fo1lowing reasons : . 1_ [ X ] ClaimNos. : 1 - 10 , 30 - 31 because they relate to subject matter not required to be searched by this Authority , namely : Claims 1 - 25 , and 30 - 31 are directed to methods for treatment of the human or animal body by surgery or therapy which the. International Search Authority is not required to search. HoweVer , this Authority has carried out a search based on the alleged effects or purposes / uses of the compositions deﬁned in claims 1 - 10. 2. [ ] ClaimNos. : . because they relate to parts of the international application that do not comp1y with the prescribed requirements to such an eXtent that no meaningful international search can be carried out , speciﬁcally : . 3. [ ] ClaimNos. : . because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4 ( a ) . . B0x N0. III ObserVati0ns Where unity of inVenti0n is lacking ( Continuation 0f item 3 0f ﬁrst sheet ) . . . This Internationa1 Searching Authority found mu1tiple inVentions in this internationa1 app1ication , as fo11ows : . The c1aims are directed to a plura1ity of a11eged inventive. See extra sheet f0r claim groups and eXplanation. 1. [ ] As all required additional search fees were timely paid by the applicant , this international search report coVers all. searchable claims. 2. [ ] As all searchable claims could be searched without effo1t justifying additional fees , this Authority did not inVite. payment of additional fees. 3. [ ] As only some of the required additional search fees were time1y paid by the app1icant , this international search rep0rt coVers only those claims for which fees were paid , speciﬁcally claim Nos. : . 4. [ X ] No required additional search fees were timely paid by the applicant. Consequently , this international search report is. restricted to the inVention ﬁrst mentioned in the claims ' , it is coVered by claim Nos. : 1 _ 10a 26 , 28 — 31 & 33 - 37. Remark 011 Pr0test [ ] The additional search fees were accompanied by the applicants protest and , where applicable , . the payment of a protest fee. [ ] The additiona1 search fees were accompanied by the app1icant ' s protest but the app1icab1e protest. fee was not paid within the time 1imit speciﬁed iii the inVitation. [ ] No protest accompanied the payment of additional search fees. . Form PCT / ISA / 2l0 ( continuation of ﬁrst sheet ( 2 ) ) ( July 2009 ) Page 2 of 6. . . INTERNATIONAL SEARCH REPORT mtemati0na1app1ication No. PCT / CA2009 / 001440. . . C ( Continuation ) . DOCUNTENTS CONS1DERED TO BE RELEVANT. . Category * Citation of document , with indication , where appropriate , of the re1eVant passages ReleVant to claim No. . X WO 2007 / 074344 A1 05 - July - 2007 KNOX 26 , 28 - 29 , 33 — 37 USe 0f aipha - hydmxy carb0nyl c0mp0undS as reducing agcntS. D4 : See abstract , claims 42 - 47. . . . . . Form PCT / ISA / 210 ( continuation of second sheet ) ( Ju1y 2009 ) Page 4 of 6. INTERNATIONAL SEARCH REPORT. . . International application No. . . . . . . Information on patent fami1y members PCT / CA2009 / OO144O Patent Document Pub1ication Patent Fami1y Pub1ication Cited in Search Report Date Member ( s ) Date WO 0115692A1 08 - 03 - 200l AT 401071T lS - 08 - 2008 AU 783283B2 13 - 10 - 2005 AU 5785399A 26 - 03 - 200l CA 2348565A1 08 - 03 - 2001 CN ll6530lC OS - 09 - 2004 CN 1329489A 02 - 01 - 2002 DE 69939l23D1 28 - 08 - 2008 DK 1124550T3 17 - 11 - 2008 EP 1124550A1 22 - 08 - 200l EP 1124550A4 21 - 08 - 2002 EP 1124550B1 l6 - 07 - 2008 EP 1124550B9 05 - 11 - 2008 ES 23 lO941T3 l6 - 01 - 2009 JP 2003508437T 04 - 03 - 2003 NO 326995Bl 30 - 03 - 2009 NO 20012027A 20 - 06 - 2001 NO 200 l2027D0 25 - 04 - 200l NZ 511396A 29 - 08 - 2003 PT 1124550E 29 - 08 - 2008 TW 245643B 21 - 12 - 2005 US 2004092549Al l3 - 05 - 2004 WO 0115692A8 11 - 10 - 2001 WO 2007074344Al 05 - 07 - 2007 AU 2006329678Al 05 - 07 - 2007 CA 2635388A1 05 - 07 - 2007 CN lOl389320A lS - O3 - 2009 EP 1951213A1 06 - 08 - 2008 GB 0526552D0 08 - 02 - 2006 ] P 2009522244T 11 - 06 - 2009 KR 2008009l354A lO - l0 - 2008 MX 2008008616A 27 - 1 1 - 2008 NO 20082852A 29 - 09 - 2008 WO 2007074344A8 27 - 12 - 2007 Form PCT / lSA!210 ( patent family anneX ) ( July 2009 ) Page 5 of 6. . . . INTERNATIONAL SEARCH REPORT mtemati0na1app1ication No. PCT / CA2009 / 001440. . . . Continuati0n 0f BOX III : Observati0ns Where Unity of Invention is Lacking The claims are directed to a plura1ity of a11eged inventive concepts as f0llows : . Gr0up A - Claims 1 - 10 , 26 , 28 - 31 ( in part ) , and 33 - 37 ( in part ) are directed t0 the use of a tetrose ( i. e. a 4 carbon sugar ) , derivatives thereof , or c0mp0sitions thereof for the treatment of cancer or inhibiting cancer cell grthh. Gronp B - C1aims 11 - 14 ( in part ) , 15 , 17 - 19 ( in part ) , 28 - 31 ( in part ) , 33 - 35 ( in part ) , and 37 ( in part ) are directed to the use of a tetr0se , derivatives there0f , or 00mpositions thereof for enhancing / increasing ce1l viabi1ity under conditions of limited energy supply. Gr0up C - C1aims 11 - 14 ( in part ) , 16 , 17 - 19 ( in part ) , 20 - 25 , 27 , 28 - 31 ( in part ) , and 33 - 37 ( in part ) are directed to the use 0f a tetrose , derivatives there0f , or compositi0ns thereof for enhancing cel1viabi1ity Wherein the ce1l has a mitochondria1 disorder , 0r f0r treating mit0chondrial dis0rders including neurodegenerative disease , Alzheimers disease , Parkinsons disease , Huntingtons disease , cardiovascular disease , stroke , obesity , diabetes , mu1tiple sclerosis , systematic lupus erythematosis , rheumatoid arthritis , schizophrenia , bipo1ar disorder , depression , ataXia , autism , epi1epsy , migraine , Batten disease , Lactic acidemia , Lebers disease , mit0ch0ndrial cardiomyopathy and myopathy , paraplegin , NASH , and Wi1sons disease. Gr0up D - Claim 32 and 37 ( in part ) are directed to a dietary composition c0mprising a tetrose or prodrug thereof for no particular therapeutic use. The claims must be 1imited to one inventive c0ncept as set out in Ru1e 13 of the PCT. The documents referred to on page 1 of present description indicate that tetroses are well known compounds. Thus tetr0ses cann0t be considered as a technical feature which 1inks al1 claims by a single genera1 inventive concept. Furthermore , there is no sing1e genera1 inventive technica1 feature 1inking the treatment of cancer or inhibiting cancer ce11 grthh ( Group A ) with the treatment of any of the ab0ve deﬁned mitochondrial disorders ( Group C ) . Nor is there a single genera1 inventive technical feature linking the treatment of cancer or inhibiting cancer cell grthh ( Group A ) with enhancing\increasing cell viability under conditions of 1imited energy supp1y ( Group B ) . . Form PCT / ISA / 2l0 ( eXtra sheet ) ( July 2009 ) Page 6 of 6